NEPHROLOGY Flashcards

Question

FSH 2025 BPT MCQ RECALL QUIZ A 31-year-old female presents with asymptomatic hypertension (average daytime BP of 160/90mmHg on ambulatory BP monitoring). She has an abdominal bruit and a history of urinary tract infections as a child. She has normal kidneys on renal USS and a bland urine. ANA is negative. What is the most likely reason for her hypertension? A. Scleroderma B. Pheochromocytoma C. Primary Hyperaldosteronism D. Renal Artery Fibromuscular Dysplasia

Answer 1

ANSWER - D - RENAL ARTERY FIBROMUSCULAR DYSPLASIA Non-atherosclerotic arterial disease that is characterised by abnormal cellular proliferation and distorted architecture of the arterial wall. Commonly present with treatment-resistant HTN, young strokes or SCAD (particularly women) For patients with suspected renal artery FMD, whole-body CTA is the initial imaging modality of choice. Contrast-enhanced MRA is an alternative to CTA when CTA is contraindicated. In the absence of contraindication, antiplatelet therapy (i.e. aspirin 75–100 mg daily) is reasonable for patients with FMD to prevent thrombotic and thromboembolic complications. BP control to prevent complications 1st line ACE/ARB (BB if SCAD) Angioplasty alone is the revascularization approach of choice for renal artery FMD, and stenting is reserved for the treatment of procedural complications, such as a flow-limiting dissection or arterial rupture.

Answer 2

ANSWER - A - NA-K-Cl co-transporters (NKCC2) 1 Brain, 2 Kidneys! NKCC1 therefore = Brain NKCC2 = Kidneys Blockade of the NKCC2 transporter decreases the reabsorption of sodium potassium and chloride in the thick ascending limb This increases the delivery of sodium potassium and chloride to the distal nephron. This reduces water reabsorption in the collecting ducts, therefore increasing urine output, K excretion

Answer 3

ANSWER - D - D-LACTIC ACIDOSIS

Answer 4

ANSWER - B - GRANULOMATOSIS WITH POLYANGIITIS GPA is a small vessel vasculitis (ANCA associated - PR3). It commonly presents with ENT symptoms as well as lung and kidney involvement. Skin manifestations can include palpable purpura. HSP is an IgA vasculitis that most commonly occurs in children. It is characterised by the triad of purpura, arthritis, and abdominal pain. 40% of patients have kidney involvement and often presents as haematuria but lung involvement is rare. PAN is a medium-sized vessel vasculitis and often presents with constitutional symptoms such as fever, malaise, loss of appetite and weight loss. Skin changes include palpable purpura and livedo reticularis. Kidney impairment is related to the vasculitis affecting the renal artery, leading to protein and blood in the urine. Patients also often have peripheral neuropathy. Lungs are not commonly affected. It is associated with Hep B and hairy cell leukaemia. Takayasu’s arteritis (or pulseless disease), is a large vessel vasculitis. The inflammation leads to arterial stenosis, thrombosis and aneurysms. This can manifest with renal artery stenosis

Answer 5

ANSWER - B - GITELMAN Gitelman syndrome, also known as familial hypokalaemia-hypomagnesemia, is a rare autosomal recessive genetic disorder of kidney physiology. Typically affects the distal convoluted tubule and causing symptoms of dehydration. The electrolytes affected are primarily potassium, magnesium, and calcium. (Acts like a Thiazide Diuretic) Most cases of Gitelman syndrome are caused by mutations in the SLC12A3 gene Bartter’s is also autosomal recessive, can arise from mutations in multiple sites (such as NKCC2 (SLC12A1), ROMK (KCNJ1), Barttin (BSND)) and causes secondary hyperaldosteronism through impaired reabsorption of Na, K and Cl (ie: acts like frusemide)

Answer 6

ANSWER - A - CYCLOPHOSPHAMIDE + LOW DOSE GLUCOCORTICOID 2-step question: Requiring you to pick the diagnosis of rapidly progressive glomerulonephritis, then consider treatment approach Microscopic glomerular crescent formation + ANCA positivity is the key Low dose glucocorticoids have similar efficacy to standard dose, with fewer side effects (PEXIVAS). Oral cyclophosphamide incurs much larger cumulative exposure to CYC than IV and a higher risk of bladder cancer. The impact on fertility is proportional to cumulative exposure dose. Rituximab is equivalent to oral cyclophosphamide for induction treatment (RAVE trial). Plasma exchange does not improve renal outcomes (PEXIVAS). May still be indicated though if severe complications such as pulmonary haemorrhage.

Answer 7

ANSWER - A - DUPLEX RENAL ULTRASOUND

Answer 8

ANSWER - B - DELAY PROGRESSION OF CKD FOR PATIENTS WITH STAGE 3 CKD CAUSED BY IGA NEPHROPATHY Patients with IgA were the major group included in the DAPA-CKD Trial (NEJM 2020) and a post-hoc analysis supported a protective effect of dapagliflozin in IgA nephropathy. Patients with CKD caused by T1D and polycystic kidney disease were excluded from DAPA-CKD. The glycosuric effects of SGLT2i are very modest when eGFR<30, hence very modest/minimal hypoglycaemic effect in CKD 4/5. Little data exists for safety and efficacy of SGLT2i in kidney transplant recipients. No PBS indication currently for dialysis or transplant patients

Answer 9

ANSWER - C - SYMPATHETIC NERVE STIMULATION Renin secretion in response to sympathetic nerve stimulation explains why beta-blockers can lead to false positive ARR in the screening for hyperaldosteronism. Hypokalaemia, Angiotensin II and Atrial Naturetic Peptide suppress renin due to negative feed-back, explaining why ACEi/ARBs and hypokalemia can lead to false negative ARR.

Answer 10

ANSWER - B - ? Primary Hyperparathyroidism: Adenoma or Hyperplasia, effects on Kidney and Bones. Phosphaturic effect Treatment in patients with Symptoms: Nephrolithiasis/ symptomatic hypercalcemia: should have parathyroid surgery, which is the only definitive therapy. Parathyroidectomy is an effective therapy that cures the disease, decreases the risk of kidney stones, improves bone mineral density (BMD), and may decrease fracture risk and modestly improve some quality-of-life measurements Secondary and Tertiary Hyperparathyroidism: Secondary hyperparathyroidism occurs when excess PTH is excreted as a result of a chronic condition that leads to hypocalcemia. Examples of these disease states include vitamin D deficiency, chronic kidney disease (CKD), and intestinal malabsorption. Tertiary hyperparathyroidism marked by hypercalcemia and excessive PTH secretion, can occur after prolonged secondary hyperparathyroidism. The persistent parathyroid stimulation leads to gland hyperplasia, resulting in autonomous production of PTH despite correction of calcium levels. (Renal failure who receives a Tx)

Answer 11

ANSWER - C - ATN ACUTE TUBULAR NECROSIS ATN: Principally due to all the causes of severe pre-renal disease, particularly hypotension, sepsis, and nephrotoxins. The FENa is typically less than 1 percent in pre-renal disease (indicative of the sodium retention) and above 2 percent in ATN. AIN: characterised by an inflammatory infiltrate in the kidney interstitium. Drugs, particularly antibiotics, are the most common cause of AIN. Usually seen after 10-14 days up to months of commencing the offending drug. Rhabdomyolysis:The clinical manifestations of rhabdomyolysis include myalgias, weakness, red to brown urine due to myoglobinuria, and elevated serum muscle enzymes, including creatine kinase (CK). Usually have anuric/oliguric phase Hyperoxaluria: Primary hyperoxaluria (PH) is a rare inborn error of glyoxylate metabolism characterised by the overproduction of oxalate, which is deposited as calcium oxalate in various organs.

Answer 12

ANSWER - C - USE OF NORMAL SALINE INCURS AN INCREASED RISK OF HYPERCHLORAEMIC METABOLIC ACIDOSIS IN AKI Saline contains a supra-physiological concentration of chloride (154 mmol/L) and high-volume infusions of normal saline may cause hyperchloraemia, leading to acidosis and renal hypo-perfusion. Restriction of IV fluid volume in patients with septic shock in ICU did not alter mortality or dialysis requirement (Meyhoff et.al, NEJM 2022). Fluids should be used to restore BP before resorting to inotropes in patients with septic shock. Colloids do not yield superior survival versus crystalloid in this situation, and use of starch was found to increase mortality.

Answer 13

ANSWER - A - NEPHROGENIC DIABETES INSIPIDUS Minimal change to urine osmolality during desmopressin response testing indicative of nephrogenic DI In osmotic diuresis the urine osmolality is usually >600 with Normal range serum Sodium Salt-wasting nephropathies will have low serum Sodium + extracellular fluid losses Psychogenic polydipsia is elicited on Hx and fluid restriction will improve urine osmolality, typically >700

Answer 14

ANSWER - D - STATINS ARE EFFECTIVE IN REDUCING CV EVENTS IN CKD SHARP STUDY: risk of the primary outcome of major atherosclerotic events other than death was reduced by simvastatin/ezetimibe among a wide range of pts with CKD SHARP and AURORA studies did not demonstrate benefit in introducing statings in dialysis patients Statins are superior to Fibrates KDIGO Guidelines: 2.1.1: In adults aged 50+ years with eGFR<60 ml/min/1.73 m2 but not treated with chronic dialysis or kidney transplantation (GFR categories G3a-G5), we recommend treatment with a statin or statin/ezetimibe combination. (1A) 2.1.2: In adults aged Z50 years with CKD and eGFRZ60 ml/min/1.73 m2 (GFR categories G1-G2) we recommend treatment with a statin. (1B) 2.2: In adults aged 18–49 years with CKD but not treated with chronic dialysis or kidney transplantation, we suggest statin treatment in people with one or more of the following (2A): K known coronary disease (myocardial infarction or coronary revascularization) K diabetes mellitus K prior ischemic stroke K estimated 10-year incidence of coronary death or non-fatal myocardial infarction 410% 2.3.1: In adults with dialysis-dependent CKD, we suggest that statins or statin/ezetimibe combination not be initiated. (2A) 2.3.2: In patients already receiving statins or statin/ezetimibe combination at the time of dialysis initiation, we suggest that these agents be continued. (2C) 2.4: In adult kidney transplant recipients, we suggest treatment with a statin. (2B) https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2013-Lipids-Guideline-English.pdf

Answer 15

ANSWER - B - SPIRONOLACTONE (MRA) History of treatment resistant HTN on maximal guideline-based therapeutic doses is suggestive of Conn Syndrome Conn’s is highly responsive to Spironolactone The best data come from the PATHWAY-2 trial, a randomised, double-blind crossover study comparing hypertension treatment doses of spironolactone (25 to 50 mg/day) with other agents

Answer 16

ANSWER - B - IV IRON INFUSION We recommend giving iron to most CKD patients who have a TSAT ≤20 percent and a serum ferritin concentration ≤100ng/mL. More likely to have absolute iron deficiency than patients with normal renal function We give iron to most anemic CKD patients who have a TSAT ≤30 percent and ferritin ≤500 ng/mL. While most CKD patients with TSAT of 20 to 30 percent and ferritin 100 to 500 ng/mL will have normal iron stores on bone marrow biopsy, many will respond to iron with an increase in Hb or decrease in erythropoiesis-stimulating agent (ESA) dose CKD patients who have a TSAT >30 percent are unlikely to respond to iron, as are patients with ferritin levels >500 ng/mL

Answer 17

The correct answer is amyloid nephropathy. The clinical presentation of this 70-year-old man with significant proteinuria, impaired renal function, and a history of chronic osteomyelitis following a fracture, are highly suggestive of Amyloid nephropathy. Amyloid nephropathy, also known as renal amyloidosis, involves the deposition of amyloid proteins in the renal parenchyma, leading to progressive kidney damage. Amyloidosis can be systemic or localised, and the kidney is one of the most commonly affected organs in systemic amyloidosis. The condition can lead to nephrotic syndrome, characterized by significant proteinuria, hypoalbuminemia, and sometimes renal insufficiency. In this patient’s case, the longstanding history of chronic osteomyelitis could serve as a chronic inflammatory stimulus for the production of serum amyloid A (SAA), a precursor to amyloid protein. Chronic infections are known risk factors for secondary (reactive) amyloidosis (AA type), where prolonged inflammation leads to the accumulation of amyloid proteins. The significant proteinuria (2.90 g/day) and the presence of red blood cells in the urine, suggesting a glomerular origin, align with amyloid nephropathy’s presentation. Although the renal ultrasound shows normal renal size and morphology, amyloid deposits may not alter the gross appearance of the kidneys early in the disease process. Interstitial nephritis in this case, seems less likely due to the pattern of significant proteinuria and the absence of active urinary sediment typical for interstitial nephritis (e.g., white blood cell casts). Epi-membranous glomerulonephritis could potentially be considered due to the significant proteinuria and glomerular haematuria, however this diagnosis is less likely in light of the patient’s history of chronic osteomyelitis, which is a known risk factor for amyloidosis. The lack of a history of progressive renal decline and the absence of segmental scarring noted on imaging makes FSGS a less likely diagnosis. The patient’s glucose intolerance and elevated HbA1c suggest a prediabetic state, but the absence of a longstanding history of diabetes with associated microvascular complications makes diabetic nephropathy less likely. Additionally, diabetic nephropathy would not typically present abruptly in the context of well-preserved renal function and without other diabetic complications. So given the patient’s chronic inflammatory history due to osteomyelitis and the renal presentation, amyloid nephropathy becomes a plausible diagnosis, potentially secondary to chronic infection leading to AA amyloidosis. Further diagnostic steps, such as a renal biopsy with staining for amyloid proteins, would be essential to confirm the diagnosis and guide management. See differential diagnoses of nephropathies with proteinuria

Answer 18

The correct answer is hyperlipidemia. Rapamycin, also known as Sirolimus, is an immunosuppressive drug often used to prevent organ transplant rejection. Unlike some other immunosuppressants, Sirolimus has a unique mechanism of action as it inhibits the mammalian target of rapamycin (mTOR), a key regulator of cell growth, proliferation, and survival. One of the well-documented side effects of Sirolimus is hyperlipidemia, which includes elevated levels of cholesterol and triglycerides. This side effect is relatively common and may require treatment with lipid-lowering agents in patients receiving Sirolimus. While some immunosuppressive medications, particularly corticosteroids and calcineurin inhibitors like tacrolimus and cyclosporine, are associated with an increased risk of new-onset diabetes after transplantation, Sirolimus is not primarily known for this side effect. Hypersensitivity reaction is also not among the most commonly reported side effects of Sirolimus. In general, certain immunosuppressive drugs can increase the risk of malignancies due to their action on the immune system. However, Sirolimus has been shown in some studies to have antiproliferative effects, which might reduce the risk of certain types of cancer compared to other immunosuppressants. Thus, malignancy is not the most likely side effect associated with Sirolimus. Sirolimus is often used in transplant patients specifically because it lacks the nephrotoxic effects associated with calcineurin inhibitors (such as cyclosporine and tacrolimus). While it can have other renal-related side effects (like proteinuria), direct nephrotoxicity is not typically a concern with Sirolimus, making it a preferred option in certain patients with renal impairment. Given its profile, hyperlipidemia is the side effect most commonly associated with Sirolimus. Patients on Sirolimus often require monitoring of their lipid profiles and may need management with lipid-lowering medications.

Answer 19

✅ Correct answer: Post-streptococcal glomerulonephritis Why PSGN is the least likely to recur (and cause graft failure) PSGN is infection-triggered, not an ongoing intrinsic immune disease Once the strep antigen is gone → the immune process burns out So after transplant: No persistent driver Very low recurrence risk Rarely causes graft loss 🧠 Exam vibe: “one-off immune hit, not a chronic autoimmune problem” Why the others are WRONG (aka recur and ruin grafts 😬) ❌ IgA nephropathy Very high recurrence rate (up to ~50%) Can absolutely cause graft dysfunction Often sneaky and slow but real ❌ FSGS High recurrence risk (especially primary FSGS) Can recur early (days–weeks) Major cause of graft failure 🔥 exam favourite ❌ Membranous GN Moderate recurrence risk Can recur years later Anti-PLA2R can persist ❌ Mesangiocapillary GN (MPGN type 1) High recurrence risk Often driven by complement dysregulation or immune complexes Poor graft outcomes One-liner to lock it in 🔒 “Post-streptococcal GN is least likely to recur post-transplant because it is a self-limited, infection-related disease rather than a persistent immune process.” *** The correct answer is Post streptococcal glomerulonephritis. When considering the likelihood of recurrence of glomerulonephritis post-transplant, and the potential impact on graft failure, the type of glomerulonephritis is a key factor. Post streptococcal glomerulonephritis (PSGN) is less likely to recur post-transplant and cause graft failure among the options listed. PSGN is usually a consequence of infection with specific strains of Group A beta-hemolytic streptococci, typically resolving with supportive treatment and eradication of the infection. The immune response leading to PSGN is usually transient, and once resolved, it does not inherently predispose to recurrence, especially in a transplanted kidney. IgA Nephropathy is one of the most common forms of glomerulonephritis that can recur in the transplanted kidney. Recurrence rates have been variably reported, and while it may not always lead to graft failure, its potential for recurrence is significantly higher than PSGN. Membranous Glomerulonephritis can also recur in the transplanted kidney, especially if the underlying cause of the nephropathy, such as autoantibodies (e.g., anti-PLA2R antibodies), persists post-transplant. Mesangiocapillary Glomerulonephritis Type 1 (MCGN Type 1), also known as membranoproliferative glomerulonephritis type 1, can recur in the transplant kidney. Its recurrence can be associated with significant graft dysfunction and loss. Focal and Segmental Glomerulosclerosis (FSGS) has a high recurrence rate post-transplant, and recurrent disease can lead to rapid graft loss. It’s one of the more concerning forms of glomerulonephritis in the context of kidney transplantation due to its recurrence potential and impact on the graft. It is important to note that thirty to fifty percent of kidney transplant recipients have glomerular diseases as the underlying causes of end-stage renal failure. While recurrence of glomerulonephritis is an important cause of late renal allograft failure, the risk factors for recurrence are largely unknown. IgA nephropathy: Most common type of GN worldwide and is the primary cause of renal failure in 20% of kidney transplant recipients. Recurrent IgA nephropathy is common after transplantation and recurrence rate reported for patients with renal biopsies for clinical symptoms ranged from 13–50%. Clinical manifestations are similar to primary IgA nephropathy and include microscopic hematuria, proteinuria and slow decline in renal function. Focal and segmental GN: Primary FSGS has a recurrence rate of 20–50% after kidney transplantation leading to graft failure in 13–20% of patient in 10 years after kidney transplantation. Clinical manifestations of recurrent FSGS include early onset of massive proteinuria, usually within first year post-transplant, hypertension and graft dysfunction. Membranoproliferative (Mesangiocapillary) GN: Both type I (with mesangial and subendothelial deposits) and type II (dense deposit disease) primary MPGN have high rates of recurrence after transplantation. Type I MPGN recurs in 20–50% of patients but recurrent disease is much more frequent in type II disease, and up to 80–100% of patients are affected. These patients usually present with nonnephrotic range proteinuria within the first year posttransplant and slowly declining renal function. Risk factors for recurrence include HLA-B8DR3, living related donors and previous graft loss from recurrence. There is no correlation between complement level and recurrence risk. Graft loss due to recurrence occur in 15–30% of patients after 5 years. Membranous GN: Idiopathic membranous nephropathy(MN) recurs in 10–30% of patients after kidney transplantation. Recurrent disease should be differentiated from de novo MN, which is the most common de novo glomerulopathy in renal allografts. The disease is characterized by nephrotic range proteinuria. Mean onset time is approximately 10 months post-transplant as compared with the more insidious and later onset of symptoms in de novo MN, an entity thought to be related to chronic rejection. Graft failure from recurrence occurs in 10–15% of patients after 10 years.

Answer 20

The correct answer is Mesangial hypercellularity. First and foremost, given the symptoms of sore throat followed by hematuria, it is unlikely that a renal biopsy would show no change, as the above clinical presentation would typically suggest an active glomerular process. So considering these symptoms, the suspicion of acute post-infectious glomerulonephritis (commonly post-streptococcal glomerulonephritis, PSGN) is high. This condition typically occurs after an infection with certain strains of Group A beta-hemolytic streptococci, affecting the throat or skin. PSGN is characterized histologically by an increase in the number of cells in the mesangial regions of the glomeruli, known as mesangial hypercellularity. This finding is due to the proliferation of mesangial cells and infiltration by leukocytes, in response to immune complex deposition in the glomerulus following the streptococcal infection. Therefore, the most likely renal biopsy finding would be Mesangial hypercellularity. While endothelial cell proliferation can be seen in some types of glomerulonephritis, such as in rapidly progressive glomerulonephritis (RPGN), the clinical context provided here fits better with mesangial hypercellularity typical of acute post-infectious glomerulonephritis. The finding of basement membrane thickening is more characteristic of chronic or progressive glomerular diseases, such as diabetic nephropathy or membranous nephropathy, rather than the acute presentation described in this case. Capillary wall necrosis would be more indicative of a more severe form of glomerular injury, such as that seen in severe vasculitis or rapidly progressive glomerulonephritis (RPGN). The clinical presentation provided does not suggest such an aggressive course. In summary, given the acute onset of symptoms following a sore throat and the presence of hematuria in a teenager, the most likely histopathological finding on renal biopsy would be mesangial hypercellularity, consistent with acute post-infectious glomerulonephritis. How to differentiate between IgA nephropathy and post-streptococcal glomerulonephritis? post-streptococcal glomerulonephritis is typically associated with low complement levels main symptom in post-streptococcal glomerulonephritis is proteinuria (although haematuria can occur) there is typically an interval between URTI and the onset of renal problems in poststreptococcal glomerulonephritis The basics of IgA nephropathy: also called Berger’s disease or mesangioproliferative glomerulonephritis commonest cause of glomerulonephritis worldwide pathogenesis unknown, ?mesangial deposition of IgA immune complexes histology: mesangial hypercellularity, positive immunofluorescence for IgA & C3 Common clinical presentation: young male, recurrent episodes of macroscopic haematuria typically associated with mucosal infections e.g., URTI nephrotic range proteinuria is rare renal failure Associated conditions: alcoholic cirrhosis coeliac disease/dermatitis herpetiformis Management: steroids/immunosuppressants not be shown to be useful Prognosis 25% of patients develop ESRF markers of good prognosis: frank haematuria markers of poor prognosis: male gender, proteinuria (especially > 2 g/day), hypertension, smoking, hyperlipidaemia, ACE genotype DD.

Answer 21

The correct answer is 110-120g/dl In individuals with chronic renal failure (CRF), especially those undergoing haemodialysis or peritoneal dialysis, there is often anaemia, which is characterized by lower-than-normal levels of haemoglobin in the blood. The target haemoglobin range for patients with chronic renal failure, including those undergoing renal replacement therapy (dialysis), has been a subject of debate and has evolved over the years. The optimal haemoglobin target may vary based on individual patient factors, co-morbidities, and current clinical guidelines. Based on the National Kidney Foundation (NKF) Guidelines (2020): – For most adult patients with chronic kidney disease (CKD) who are not on dialysis, the NKF guidelines recommend targeting a haemoglobin level of 110-120 g/L. The target range may be individualised based on factors like symptoms and co-morbidities. – For patients on dialysis, the NKF suggests a target haemoglobin level in the range of 110-115 g/L. Based on the KDOQI Guidelines (Kidney Disease Outcomes Quality Initiative): – The KDOQI guidelines were a widely referenced set of recommendations for managing CKD and anaemia but were last updated in 2007. They suggested a target haemoglobin range of 110-120 g/L for patients with CKD not on dialysis and 110-120 g/L for those on dialysis.

Answer 22

The correct answer is No prophylaxis needed. Earlier studies by Mueller et al (Arch Intern Med 2002) demonstrated the superiority of isotonic saline compared to half-isotonic (0.45% sodium chloride plus 5% glucose) in the prevention of contrast induced nephropathy in patients undergoing coronary angioplasty. But more recently a randomised controlled study published in Lancet 2017 (AMACING study) reported that no prophylaxis to be non-inferior and cost-saving in preventing contrast-induced nephropathy compared with intravenous hydration. Recent evidence (PRESERVE trial) has also shown that intravenous sodium bicarbonate and oral acetylcysteine is no more effective than normal saline in reducing the incidence of contrast-induced acute kidney injury. So based on the above study, we can conclude that no prophylaxis is necessary in preventing contrast induced nephropathy.

Answer 23

The correct answer is Caucasian population. In the context of proliferative lupus nephritis, a form of kidney involvement in Systemic Lupus Erythematosus (SLE) characterized by significant inflammation and proliferation within the glomeruli, various factors can influence the prognosis. But among the options listed, the one that is NOT typically considered a poor prognostic indicator is Caucasian population. Ethnicity does play a role in the prognosis of lupus nephritis, with certain ethnic groups showing more severe disease and poorer outcomes. However, it is generally observed that African American patients and those of Hispanic descent tend to have a more severe course of lupus nephritis compared to Caucasian patients. Therefore, being of the Caucasian population is not typically associated with poorer outcomes in lupus nephritis and, in comparative terms, might even be considered to have a relatively better prognosis. Having an elevated serum creatinine at presentation is considered a poor prognostic factor because it indicates significant renal impairment at the time of diagnosis. Higher levels of serum creatinine at presentation are associated with a greater degree of kidney damage and a higher risk of progression to end-stage renal disease (ESRD). The inability to achieve clinical remission after treatment is a strong predictor of poor long-term kidney outcomes in lupus nephritis. Patients who do not respond to therapy are at a higher risk for continued renal damage and decline in kidney function. As noted, African American patients with SLE, including those with lupus nephritis, tend to have a more aggressive disease course and poorer outcomes compared to their Caucasian counterparts. This includes a higher likelihood of progression to ESRD. The Chronicity Index is a histopathological score that assesses the degree of irreversible damage (such as fibrosis and sclerosis) in the kidney tissue. A high Chronicity Index on renal biopsy in lupus nephritis is associated with poorer renal outcomes because it reflects the extent of permanent damage that is less likely to respond to immunosuppressive therapy. In summary, among the options provided, being part of the Caucasian population is not considered a poor prognostic indicator for proliferative lupus nephritis.

Answer 24

The correct answer is Hemodialysis as initial dialysis modality. In patients with end-stage renal failure (ESRF), preserving residual renal function (RRF) is crucial for maintaining fluid balance, electrolyte homeostasis, and toxin clearance, and it has been associated with improved survival and quality of life. Among the interventions listed, the one that is least helpful in preserving RRF is Hemodialysis as initial dialysis modality. Hemodialysis, particularly when initiated as the first dialysis modality, may be less favorable for preserving residual renal function compared to peritoneal dialysis (PD). The intermittent nature of hemodialysis can lead to significant fluctuations in intravascular volume and blood pressure, potentially contributing to renal ischemia and further decline in RRF. In contrast, peritoneal dialysis is a continuous process and tends to be more gentle with fluid removal, which can help preserve RRF as demonstrated by a study by Moist et al. The use of RAAS inhibitors, such as ACE inhibitors or ARBs, can be beneficial in preserving RRF by reducing intraglomerular pressure and proteinuria, which are factors that can accelerate renal decline. In patients on peritoneal dialysis, episodes of peritonitis can lead to inflammation and vascular changes that may adversely affect RRF. Preventive measures against peritonitis are crucial for maintaining the health of the peritoneal membrane and potentially preserving RRF. Exposure to nephrotoxic substances, including certain medications (e.g., NSAIDs, aminoglycosides), contrast agents, and environmental toxins, can cause acute kidney injury or exacerbate chronic renal impairment, leading to a loss of RRF. Ensuring adequate hydration and avoiding hypovolemic states are important for maintaining renal perfusion and function. Hypovolemia can lead to prerenal azotemia and acute on chronic renal failure, further compromising RRF. Therefore, while interventions like RAAS blockade, prevention of PD-associated peritonitis, avoidance of nephrotoxins, and maintaining adequate hydration are geared toward preserving RRF, choosing hemodialysis as the initial dialysis modality may not be as beneficial for this purpose compared to alternatives like peritoneal dialysis. Remember that every 1ml/min of residual native GFR, protects the patient from death on dialysis. 2 major studies to be aware of: CANUSA and NECOSAD study Further reading: The importance of residual kidney function for patients on dialysis: a critical review.

Answer 25

The correct answer is lupus serology (DsDNA, C3, C4). Lupus nephritis, a renal involvement in Systemic Lupus Erythematosus (SLE), typically presents with various renal manifestations. In lupus nephritis, acute renal impairment can occur, especially in more severe cases. This can be due to active inflammation of the glomeruli leading to compromised renal function. Lupus nephritis can present with a nephritic syndrome, characterized by hypertension, hematuria, azotemia, and oliguria. It is a result of inflammation and damage to the glomeruli causing a reduction in glomerular filtration rate (GFR) and activation of the renin-angiotensin system. Microscopic hematuria is also a common finding in lupus nephritis. Hematuria occurs due to inflammation of the glomeruli, which allows red blood cells to escape into the urine. Proteinuria is a hallmark of lupus nephritis. It occurs due to increased permeability of the glomerular basement membrane, allowing proteins to pass into the urine. It can range from mild to severe, and in some cases, it may reach nephrotic range (exceeding 3.5 grams per 24 hours). Lupus nephritis is a type-3 hypersensitivity reaction. This occurs when immune complexes are formed. Autoimmunity plays a significant role in the development of lupus nephritis leading to the production of autoantibodies that are directed against nuclear elements. Nevertheless, lupus serology is not specific for lupus nephritis. Although these abnormal serological markers are common in systemic lupus erythematosus (SLE), they are not a direct feature of lupus nephritis. Anti-double-stranded DNA (anti-dsDNA) antibodies are often elevated in SLE and are associated with disease activity, but they are not specific to renal involvement. Complement levels (C3, C4) can be low in SLE due to consumption during the inflammatory process, but again, these changes are not specific to lupus nephritis. So based on this explanation, the option that is less specific to lupus nephritis is the lupus serology (DsDNA, C3, C4) as they are not direct features of the renal involvement in the disease.

Answer 26

The correct answer is Stage IV. Lupus nephritis (LN) is a kidney disease that occurs as a complication of systemic lupus erythematosus (SLE), an autoimmune disease. Lupus nephritis can progress through different stages, each characterized by specific histological and clinical features. The stages of lupus nephritis are classified based on the International Society of Nephrology and the Renal Pathology Society (ISN/RPS) 2003 classification system, which categorizes LN into six classes or stages. Class I – Minimal Mesangial Lupus Nephritis: – This stage is characterized by minimal or no changes visible under a microscope. – There is no significant damage to the kidney tissue. – Patients may not exhibit any clinical symptoms, and renal function is typically normal. Class II – Mesangial Proliferative Lupus Nephritis: – Mesangial cells and matrix within the glomeruli are mildly increased. – There is mild inflammation and scarring in the mesangial areas. – Typically, there is minimal proteinuria, and patients may have normal kidney function. – Clinical symptoms are often mild. Class III – Focal Lupus Nephritis: – In this stage, there are focal, segmental (involving only some parts of the kidney), or global (involving the entire kidney) lesions. – There is more significant inflammation, scarring, and cellular proliferation within the glomeruli. – Proteinuria may be moderate to severe, and blood in the urine (hematuria) can be present. – Kidney function may be affected, with elevated serum creatinine levels. Class IV – Diffuse Lupus Nephritis: – This is a severe form of lupus nephritis, characterized by diffuse, global involvement of glomeruli. – There is extensive inflammation, scarring, and cellular proliferation. – Proteinuria is usually severe, and hematuria is common. – Kidney function is often significantly impaired, and individuals may experience hypertension and edema. Class V – Membranous Lupus Nephritis: – This stage primarily involves thickening of the glomerular basement membrane. – It is characterized by subepithelial immune complex deposits. – Patients may have nephrotic-range proteinuria, hypoalbuminemia, and hyperlipidemia. – Kidney function may be preserved initially, but as the disease progresses, it can lead to impaired renal function. Class VI – Advanced Sclerosing Lupus Nephritis: – This stage represents irreversible scarring and fibrosis of the kidney tissue. – There is extensive loss of functional glomeruli and tubules. – Kidney function is severely compromised, and end-stage renal disease (ESRD) may be present. In summary: Stage I: Minimal mesangial lupus nephritis(LN) Stage II: Mesangial proliferative lupus nephritis. Stage III: Focal lupus nephritis with <50% gloms involved. Stage IV: Diffuse lupus nephritis with >50% gloms involved. Stage V: Membranous lupus nephritis. Stage VI: Advanced sclerosing lupus nephritis with >90% gloms involved.

Answer 27

The correct answer is macrophage infiltration. Proliferative lupus nephritis (PLN) is a severe form of kidney involvement in systemic lupus erythematosus (SLE) characterized by significant inflammation, cellular proliferation, and damage to the renal tissue. The histological features of PLN are assessed through a kidney biopsy and are typically classified based on the International Society of Nephrology and the Renal Pathology Society (ISN/RPS) 2003 classification system. The histological findings in PLN include: 1. Glomerular Changes: – Glomerulonephritis: The glomeruli, which are the filtering units of the kidneys, often show evidence of inflammation and damage. This is characterized by an increase in the number of immune cells, such as leukocytes and mononuclear cells, within the glomeruli. – Endocapillary Proliferation: This is a key feature of proliferative lupus nephritis. It involves the proliferation of endothelial and mesangial cells within the glomerular capillaries. This results in the narrowing of the capillary lumens and decreased blood flow. – Crescents: Some individuals with PLN may develop crescents, which are cellular masses that form in Bowman’s space (the urinary space in the glomerulus). These crescents are composed of proliferating cells and can lead to glomerular scarring. 2. Tubulointerstitial Changes: – Interstitial Inflammation: Inflammatory cells infiltrate the spaces between the tubules (tubulointerstitial spaces) and may cause tissue damage. – Tubular Atrophy: Chronic inflammation and damage can lead to the atrophy (shrinkage) of the renal tubules. – Interstitial Fibrosis: Over time, fibrosis (scarring) can develop in the tubulointerstitial areas. 3. Vascular Changes: – Vascular Lesions: Vascular changes may include thickening of the vessel walls and immune complex deposits in the blood vessels. – Thrombotic Microangiopathy: Some cases of PLN may exhibit signs of thrombotic microangiopathy, which is characterized by damage to small blood vessels and the formation of microthrombi (small blood clots). 4. Immunofluorescence Studies: – Immunofluorescence studies can help identify immune complex deposits within the renal tissue. In PLN, these immune complexes typically contain antibodies (e.g., anti-double-stranded DNA antibodies) and complement proteins. 5. Electron Microscopy: – Electron microscopy is used to examine ultrastructural changes in the kidney tissue. It can reveal the detailed structure of glomerular basement membranes and the presence of immune complex deposits. The histological classification of PLN can vary from class III (focal proliferative) to class IV (diffuse proliferative) based on the extent and severity of the histological findings. Class IV is typically associated with more widespread and severe involvement of the kidney tissue. Additionally, the presence of immune complex deposits and the specific cellular changes can provide valuable information about the activity and severity of the disease. In summary, Lupus nephritis is associated with the following histological features: subendothelial immune deposits/wire loops hypercellularity leukocyte infiltration fibrinoid necrosis hyaline thrombi crescents in severe LN

Answer 28

The correct answer is intravenous immunoglobulin Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE) in which the immune system attacks the kidneys, leading to inflammation and potential kidney damage. The choice of treatment for lupus nephritis depends on the severity of the condition, the type of kidney involvement, and the patient’s overall health. Some common treatment options for lupus nephritis: 1. Immunosuppressive Medications: – Corticosteroids: High-dose corticosteroids like prednisone are often used initially to reduce inflammation and control the immune response. – Immunosuppressive drugs: These medications, such as cyclophosphamide, mycophenolate mofetil (CellCept), or azathioprine, are used to suppress the immune system and reduce kidney inflammation. 2. Biologic Therapies: – Rituximab: A monoclonal antibody that targets specific immune cells (B cells) involved in lupus nephritis. – Belimumab: A monoclonal antibody that can be used in conjunction with standard therapy for SLE, potentially improving outcomes in some patients. 3. Angiotensin-Converting Enzyme (ACE) Inhibitors or Angiotensin Receptor Blockers (ARBs): – These medications help control blood pressure and reduce proteinuria (excessive protein in the urine), which is common in lupus nephritis. 4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): – These can be used to manage pain and inflammation, but they are not typically used as primary treatment. 5. Anticoagulants: – Blood-thinning medications may be prescribed to reduce the risk of blood clots associated with lupus. 6. Dietary and Lifestyle Changes: – A low-sodium diet may be recommended to manage blood pressure and fluid retention. – Smoking cessation and alcohol moderation are essential. – Regular exercise and a balanced diet can help improve overall health. 7. Dialysis or Kidney Transplant: – In severe cases of lupus nephritis where kidney function has significantly deteriorated, hemodialysis, peritoneal dialysis, or kidney transplantation may be necessary. 8. Ongoing Monitoring: – Regular follow-up with healthcare providers is crucial to assess treatment effectiveness and adjust medications as needed. The choice of treatment depends on the specific subtype and stage of lupus nephritis, as well as individual patient factors, including age, overall health, and potential side effects of medications. Treatment plans are typically tailored to the patient’s unique needs and may involve a combination of therapies. It’s essential for individuals with lupus nephritis to work closely with a rheumatologist or nephrologist to determine the most appropriate and effective treatment approach. Principles of treatment in lupus nephritis: 1) Induction agents for lupus nephritis: Prednisone Cyclophosphamide Mycophenolate mofetil(MMF) Rituximab (refractory cases) 2) Maintenance Treatment: MMF or Azathioprine to continue for at least 2 years post remission.

Answer 29

The correct answer is Mononeuritis multiplex. Cyclophosphamide is an alkylating agent widely used in the treatment of various neoplastic diseases and autoimmune disorders. Its therapeutic efficacy is accompanied by a spectrum of potential toxicities, which can affect multiple organ systems. However, mononeuritis multiplex is not commonly associated with cyclophosphamide toxicity. Below are detailed explanation on the toxicities commonly associated with cyclophosphamide: Infertility Secondary to Gonadal Toxicity: Cyclophosphamide can cause gonadal toxicity, leading to transient or permanent infertility in both males and females. The mechanism involves direct damage to the germinal epithelium in males and the ovarian follicles in females. The risk of gonadal dysfunction is dose-dependent, with higher cumulative doses posing a greater risk. Preservation of fertility through cryopreservation of sperm or oocytes should be considered before initiating treatment in patients of reproductive age. Malignancy: Long-term use of cyclophosphamide has been associated with an increased risk of secondary malignancies, including bladder cancer, hematological malignancies (such as acute myeloid leukemia and myelodysplastic syndrome), and skin cancers. The alkylating nature of cyclophosphamide induces DNA damage, which can lead to mutations and oncogenesis. Regular monitoring and follow-up are essential for early detection and management of secondary malignancies in patients with a history of cyclophosphamide therapy. Bladder Toxicity: Cyclophosphamide metabolites, particularly acrolein, are known to cause bladder irritation and toxicity, leading to hemorrhagic cystitis. Symptoms can range from mild dysuria to severe hemorrhage. Adequate hydration and the use of mesna (2-mercaptoethane sulfonate sodium), a uroprotective agent that binds to and inactivates acrolein, are effective strategies to prevent bladder toxicity. Monitoring for urinary symptoms and prompt management of hemorrhagic cystitis are critical. Myelosuppression: Cyclophosphamide exerts its cytotoxic effects partly through myelosuppression, leading to leukopenia, anemia, and thrombocytopenia. This increases the risk of infections, bleeding, and anemia-related symptoms. Myelosuppression is dose-dependent and closely monitored through regular complete blood counts (CBCs). Dose adjustments, growth factor support, and transfusions may be necessary to manage severe myelosuppression. Herpes Zoster: The immunosuppressive effects of cyclophosphamide can reactivate latent varicella-zoster virus, leading to herpes zoster (shingles). Patients receiving cyclophosphamide, especially those with underlying immunodeficiency or those receiving concurrent immunosuppressive therapy, are at increased risk. Prophylactic antiviral therapy and vaccination against varicella-zoster virus may be considered in high-risk patients to reduce the incidence of herpes zoster. Major Infection: Cyclophosphamide-induced immunosuppression increases susceptibility to bacterial, viral, fungal, and opportunistic infections. The risk is compounded by the drug’s myelosuppressive effects. Preventive measures include prophylactic antimicrobials, vaccination, and vigilant monitoring for signs of infection. Prompt recognition and treatment of infections are paramount to prevent serious complications. In summary, while cyclophosphamide is a potent therapeutic agent, its use is associated with significant toxicities that require careful management. Regular monitoring, preventive strategies, and timely interventions are essential to minimize the adverse effects and optimize patient outcomes.

Answer 30

The correct answer is Leukocytosis. Mycophenolate mofetil is least likely to cause Leukocytosis as a side effect. This medication, primarily used as an immunosuppressant in organ transplantation and certain autoimmune diseases, is known for potential adverse effects including gastrointestinal upset, leukopenia (decrease in white blood cell count), increased risk of infections, and a potential increased risk of malignancy due to its immunosuppressive action. Leukocytosis, which refers to an increased white blood cell count, is not typically associated with mycophenolate mofetil use and does not align with the known side effect profile of the drug. Mycophenolate, whether in the form of mycophenolate mofetil (MMF) or mycophenolic acid (MPA), is an immunosuppressive medication commonly used to prevent organ rejection in transplant recipients and to treat autoimmune diseases like systemic lupus erythematosus and lupus nephritis. While mycophenolate can be effective in managing these conditions, it can also be associated with several common side effects. Some of the most frequently reported side effects of mycophenolate include: 1. Gastrointestinal Disturbances: – Nausea and vomiting: Many individuals experience mild to moderate nausea or vomiting shortly after taking mycophenolate. Taking the medication with food can help reduce these symptoms. – Diarrhea: Diarrhea is a common side effect of mycophenolate. In some cases, it can be severe and may require dose adjustments or medication changes. – Abdominal pain: Some people may experience abdominal discomfort or pain. 2. Infections: – Mycophenolate weakens the immune system’s response, making individuals more susceptible to infections, including viral, bacterial, and fungal infections. It’s essential to monitor for signs of infection and report any symptoms to a healthcare provider promptly. 3. Decreased White Blood Cell Count: – Mycophenolate can reduce the number of white blood cells, which are essential for the immune system’s defense against infections. Regular blood tests are necessary to monitor white blood cell counts. 4. Anemia: – Mycophenolate may lead to a reduction in red blood cell count, resulting in anemia. Symptoms of anemia can include fatigue, weakness, and pallor. 5. Headache: – Some individuals taking mycophenolate may experience headaches. 6. Insomnia: – Difficulty sleeping or insomnia can occur in some patients. 7. Skin Changes: – Skin rashes, itching, and sun sensitivity (photosensitivity) are reported side effects of mycophenolate. 8. Elevated Liver Enzymes: – Mycophenolate can lead to elevated levels of liver enzymes in some individuals. Regular liver function tests are necessary to monitor for liver abnormalities. 9. Hypercholesterolemia: – An increase in cholesterol levels may occur in some people taking mycophenolate. 10. Mood Changes: – Mood swings, depression, and anxiety have been reported as potential side effects, though these are less common. In summary, MMF can potentially cause the following side effects: GI upset which is a dose response side effect. Leukopenia Thrombocytopenia Anemia Infection Malignancy

Answer 31

The correct answer is Rituximab The drug of choice for refractory, relapsing lupus nephritis, particularly when traditional therapies such as cyclophosphamide or mycophenolate mofetil in combination with steroids have failed, is Rituximab. Rituximab, a monoclonal antibody that targets CD20-positive B lymphocytes, has been used off-label for lupus nephritis, especially in cases that are resistant to conventional treatment. Evidence supporting the use of Rituximab in this context includes various case series and open-label studies that have demonstrated its efficacy in inducing remission in patients with refractory lupus nephritis. The LUNAR trial, although not showing a significant difference in its primary endpoint, did indicate some benefits in certain subgroups of patients with lupus nephritis. Additionally, real-world clinical experience and retrospective analyses have further supported the role of Rituximab in managing refractory cases. It’s important to note that while cyclophosphamide and mycophenolate mofetil remain first-line options for inducing remission in lupus nephritis due to their well-established efficacy in randomized controlled trials, Rituximab may be considered in cases where these therapies are not effective, not tolerated, or contraindicated. The choice of therapy should be individualized based on the patient’s clinical presentation, previous treatment responses, and potential side effects, always considering the latest guidelines and evidence from the literature.

Answer 32

The correct answer is Tocilizumab. Tocilizumab is an anti-IL 6 receptor monoclonal antibody. One report of successful use of this agent in a case of MPA with RPGN has been published; however, there are no trial data of its use in RPGN. Pauci-immune rapidly progressive glomerulonephritis (RPGN) is a severe form of kidney disease characterized by inflammation of the glomeruli (small blood vessels in the kidneys) and rapidly declining kidney function. It is often associated with autoimmune disorders, such as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Prompt and aggressive treatment is essential to control the inflammation and prevent further kidney damage. Here are the common treatment options for pauci-immune RPGN: 1. Immunosuppressive Therapy: – Immunosuppressive medications are a cornerstone of treatment for pauci-immune RPGN. These drugs help to suppress the immune system’s overactive response that is causing kidney inflammation. Commonly used immunosuppressive medications include: – Glucocorticoids (corticosteroids): High-dose corticosteroids like prednisone are often used initially to control inflammation. – Cyclophosphamide: This medication is frequently used in combination with corticosteroids in the induction phase of treatment. – Rituximab: In some cases, rituximab, a monoclonal antibody that targets B cells, may be used as an alternative to cyclophosphamide or in combination with it. 2. Plasma Exchange (Plasmapheresis): – Plasma exchange can be used in cases of severe RPGN, especially when patients present with rapidly deteriorating kidney function. It involves removing and replacing the plasma, which may contain harmful antibodies and inflammatory factors. 3. Maintenance Therapy: – After the induction phase of treatment, maintenance therapy is typically needed to prevent disease relapse and manage the long-term course of the condition. Medications like azathioprine, mycophenolate mofetil, or low-dose glucocorticoids may be considered. 4. Supportive Care: – Patients with RPGN often require supportive care, which includes measures to manage high blood pressure, reduce fluid retention, and correct any electrolyte imbalances. Medications like angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are commonly used to control blood pressure and reduce proteinuria. 5. Kidney Transplant: – In cases of end-stage renal disease where the kidneys no longer function adequately, kidney transplant may be necessary. Patients with pauci-immune RPGN can be considered for kidney transplantation once their disease is in remission. 6. Regular Follow-Up: – Regular follow-up with a nephrologist or a rheumatologist is essential to monitor disease activity, kidney function, and medication adjustments over time. The specific treatment plan for pauci-immune RPGN can vary depending on the individual patient’s condition, the underlying cause (e.g., ANCA-associated vasculitis), and the stage of the disease. Early diagnosis and treatment are critical to achieving remission and preventing further kidney damage.

Answer 33

The correct answer is 5 to 15 years. The development of microalbuminuria in patients with Type 1 diabetes can vary widely among individuals. However, it typically occurs after several years of living with the condition. On average, many patients with Type 1 diabetes start to develop microalbuminuria roughly 5 to 15 years after their diabetes diagnosis. The risk of developing microalbuminuria is influenced by factors such as blood glucose control, blood pressure management, and genetic predisposition. Microalbuminuria is characterized by the presence of small amounts of albumin in the urine and is an early sign of kidney damage. It can progress to more severe kidney complications, such as overt proteinuria (macroalbuminuria) and diabetic nephropathy, if not effectively managed. Regular monitoring of kidney function and early intervention to control blood sugar levels and blood pressure are important for reducing the risk of kidney complications in individuals with Type 1 diabetes.

Answer 34

The correct answer is hypertension. Overt nephropathy in Type 1 diabetes mellitus is typically associated with diabetic nephropathy. Diabetic nephropathy is a serious complication of Type 1 diabetes characterized by kidney damage as a result of long-term high blood sugar levels. It is one of the most common causes of end-stage renal disease (ESRD) or kidney failure in the United States and other developed countries. The key features of diabetic nephropathy include: 1. Microalbuminuria: Diabetic nephropathy often begins with the development of microalbuminuria, where small amounts of albumin start to appear in the urine. This is an early sign of kidney damage. 2. Progression: If left untreated or poorly managed, microalbuminuria can progress to overt proteinuria (macroalbuminuria), where larger amounts of protein are excreted in the urine. 3. Kidney Dysfunction: As diabetic nephropathy advances, it can lead to a decline in kidney function, resulting in a decreased glomerular filtration rate (GFR) and impaired kidney function. 4. Increased Blood Pressure: Diabetic nephropathy is often associated with hypertension, which can further exacerbate kidney damage and increase the risk of cardiovascular complications. 5. Risk of End-Stage Renal Disease: Over time, diabetic nephropathy can progress to end-stage renal disease, where the kidneys are no longer able to adequately filter waste and excess fluids from the blood. At this stage, patients may require dialysis or kidney transplantation for survival. Controlling blood glucose levels, managing blood pressure, and early intervention are crucial to slowing the progression of diabetic nephropathy and reducing the risk of ESRD. Regular monitoring of kidney function, lifestyle modifications, and medications (e.g., angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) are often part of the management plan for individuals with Type 1 diabetes who are at risk of or have been diagnosed with diabetic nephropathy.

Answer 35

The correct answer is urine Albumin Creatinine Ratio(ACR) of >300mg/g and Albumin Excretion Rate(AER) of >300mg/24hrs. Macroalbuminuria, also known as overt proteinuria, is a stage of kidney disease characterized by the presence of a significant amount of albumin in the urine in individuals with diabetes. It is an important marker of kidney damage and is commonly associated with diabetic nephropathy. The diagnostic criteria for macroalbuminuria in men typically involve both the Albumin Creatinine Ratio (ACR) and the Albumin Excretion Rate (AER). 1. Albumin Creatinine Ratio (ACR): – ACR is a measurement of the amount of albumin excreted in the urine in relation to creatinine, a waste product produced by muscle metabolism. ACR is expressed in milligrams of albumin per gram of creatinine (mg/g). – Macroalbuminuria is typically defined as having an ACR greater than or equal to 300 mg/g on two out of three urine collections over a 3- to 6-month period. – An ACR in this range indicates a significant amount of albumin in the urine and is a key indicator of advanced kidney disease in individuals with diabetes. 2. Albumin Excretion Rate (AER): – AER is a measure of the absolute amount of albumin excreted in the urine over a 24-hour period. It is often used in clinical research studies and can provide a more precise measurement of urinary albumin excretion than ACR. – In general, an AER greater than 300 mg per 24 hours is considered indicative of macroalbuminuria and is a sign of severe kidney damage. It’s important to note that the definitions and diagnostic criteria for macroalbuminuria can vary slightly among medical organizations and guidelines. However, the ACR of 300 mg/g and the AER of 300 mg per 24 hours are commonly used thresholds to identify macroalbuminuria in men with diabetes and are indicative of advanced diabetic nephropathy.

Answer 36

The correct answer is ACE inhibitors. Angiotensin-converting enzyme (ACE) inhibitors are a class of medications commonly used to slow down the progression of diabetic nephropathy, a kidney disease that results from diabetes. These drugs primarily work by targeting the renin-angiotensin-aldosterone system (RAAS), a complex hormonal system that regulates blood pressure and fluid balance in the body. Here’s how ACE inhibitors slow down the progression of diabetic nephropathy: 1. Vasodilation: – ACE inhibitors inhibit the activity of the angiotensin-converting enzyme, which plays a key role in the RAAS. When ACE is inhibited, it leads to the reduced conversion of angiotensin I to angiotensin II. – Angiotensin II is a potent vasoconstrictor, meaning it narrows blood vessels, leading to increased blood pressure. By inhibiting the conversion of angiotensin I to angiotensin II, ACE inhibitors promote vasodilation, which results in the relaxation and widening of blood vessels. 2. Blood Pressure Reduction: – The vasodilation effect of ACE inhibitors results in a decrease in blood pressure. Lowering blood pressure is beneficial in individuals with diabetic nephropathy because high blood pressure can exacerbate kidney damage. – By reducing the pressure in the glomerular capillaries, ACE inhibitors help to protect the delicate kidney structures from excessive pressure and damage. 3. Reduction in Proteinuria: – ACE inhibitors also reduce the leakage of proteins, including albumin, into the urine (proteinuria), which is a common characteristic of diabetic nephropathy. – The reduction in proteinuria is significant because excessive excretion of proteins in the urine is a sign of kidney damage. ACE inhibitors help preserve the integrity of the glomerular filtration barrier, which is often compromised in diabetic nephropathy. 4. Slowing of Kidney Damage: – By reducing blood pressure and proteinuria, ACE inhibitors help to slow down the progression of kidney damage in individuals with diabetic nephropathy. This can delay the onset of more severe kidney complications, such as end-stage renal disease (ESRD). It’s important to note that ACE inhibitors are often used in combination with other interventions, such as blood sugar control and lifestyle modifications, to provide comprehensive management for diabetic nephropathy. These medications have proven to be effective in protecting kidney function and delaying the progression of kidney disease in individuals with diabetes.

Answer 37

The correct answer is Development of microalbuminuria. The use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in diabetic patients who are normoalbuminuric and normotensive may be protective against a specific complication: the development of microalbuminuria. Microalbuminuria is characterized by a slightly elevated level of albumin in the urine, and it is considered an early sign of kidney damage. It is often associated with diabetes and is a risk factor for the development of more severe kidney complications, such as overt proteinuria (macroalbuminuria) and diabetic nephropathy. However, research has shown that ACE inhibitors and ARBs can help prevent or delay the progression from normoalbuminuria to microalbuminuria in diabetic patients, thereby protecting against this complication. In addition to their protective effect on microalbuminuria, ACE inhibitors and ARBs have been shown to offer cardiovascular and renal protection in individuals with diabetes. They can help reduce the risk of other complications related to diabetes, such as heart disease and stroke, and are often used in diabetic management, especially in individuals at high risk of developing kidney problems or cardiovascular issues. Previous Lesson

Answer 38

The correct answer is cytomegalovirus. The symptoms of feeling generally unwell with anorexia, fatigue, arthralgia, jaundiced sclera, widespread lymphadenopathy, and hepatomegaly in a patient who is six weeks post renal transplant suggest a systemic infection. In a transplant recipient, one of the common infections to consider is cytomegalovirus (CMV) infection. Cytomegalovirus is a herpesvirus that can cause a wide range of symptoms, including fever, fatigue, and hepatitis, and it can affect multiple organs, including the liver and lymph nodes. Transplant recipients are particularly susceptible to CMV infection due to the immunosuppressive medications they take to prevent rejection. The immunosuppressive regimen in this patient (tacrolimus, mycophenolate, and prednisone) increases the risk of opportunistic infections, and CMV is a known opportunistic pathogen in transplant recipients. It’s important to note that the clinical presentation can vary, and other viral or bacterial infections may also be considered. However, given the patient’s history of renal transplant and the symptoms described, CMV infection would be a leading consideration. It’s crucial for the patient to undergo appropriate diagnostic tests, such as CMV polymerase chain reaction (PCR) or viral cultures, to confirm the diagnosis. Prompt initiation of antiviral therapy may be necessary in the context of post-transplant CMV infection. The patient should be managed in consultation with a transplant infectious disease specialist or a healthcare provider experienced in the care of transplant recipients. Ganciclovir is the treatment of choice in such patients. THE MOST COMMON OPPORTUNISTIC INFECTIONS IN THE RENAL TRANSPLANT RECIPIENT: Peri-transplant: Wound infections Herpesvirus Oral candidiasis Urinary tract infection Early (1-6 months): Pneumocystis carinii Cytomegalovirus Legionella Listeria Hepatitis B Hepatitis C Late (>6 months): Aspergillus Nocardia BK virus (polyoma) Herpes zoster Hepatitis B Hepatitis C

Answer 39

PERI-TRANSPLANT Wound infection Herpes virus Oral candidiasis UTI EARLY (1 - 6 MONTHS) PJP CMV HEP B HEP C Legionella Listeria LATE (>6 MONTHS) Aspergillus Nocardia BK virus (polyoma) Herpes zoster HEP B HEP C

Answer 40

The correct answer is Proximal convoluted tubule. The main site of potassium reabsorption in the nephron is the proximal tubule of the kidney. Approximately 65-70% of filtered potassium is reabsorbed in the proximal tubule. The reabsorption of potassium in the nephron occurs through both passive and active processes. In the proximal tubule, potassium is primarily reabsorbed passively through paracellular pathways (between cells) driven by the electrochemical gradient established by sodium reabsorption. It’s important to note that potassium handling is a dynamic process that occurs throughout different segments of the nephron. After the proximal tubule, potassium undergoes further reabsorption and secretion in the loop of Henle, distal tubule, and the collecting ducts. The distal tubule and collecting ducts are particularly important for fine-tuning potassium balance under the influence of aldosterone. Disruptions in potassium handling can lead to electrolyte imbalances and may have significant clinical implications. For example, certain diuretic medications, such as thiazide diuretics, can affect potassium reabsorption in specific segments of the nephron and may lead to alterations in potassium levels. Individuals with kidney disorders or those taking medications affecting potassium balance may require careful monitoring of their electrolyte status.

Answer 41

The correct answer is bicarbonate. In the proximal tubule of the nephron, a significant portion of the filtered bicarbonate (HCO3-) is reabsorbed. This reabsorption is crucial for maintaining the acid-base balance in the body. Approximately 65% of bicarbonate reabsorption is dependent on the activity of luminal and intracellular carbonic anhydrase and the NaH+ transporter. This process is essential for converting bicarbonate into carbon dioxide (CO2) and water (H2O), allowing CO2 to diffuse into proximal tubule cells where it is reconverted into bicarbonate and hydrogen ions. The bicarbonate is then transported back into the blood, contributing to the reabsorption of a significant percentage of bicarbonate filtered by the kidneys. This bicarbonate reabsorption process is a key function of the proximal tubule, emphasizing the critical role of this nephron segment in acid-base regulation and the conservation of bicarbonate, an essential component for buffering the body’s pH.

Answer 42

The correct answer is Hyperchloremic (normal anion gap) metabolic acidosis. The patient’s primary acid-base disturbance is a hyperchloremic (normal anion gap) metabolic acidosis, which is caused by the use of acetazolamide, a carbonic anhydrase inhibitor. Acetazolamide is a medication that inhibits the enzyme carbonic anhydrase, which plays an important role in the reabsorption of bicarbonate ions (HCO3-) in the renal tubules. In the proximal convoluted tubule (PCT), carbonic anhydrase catalyzes the reaction of carbon dioxide (CO2) and water (H2O) to form carbonic acid (H2CO3), which then dissociates into hydrogen ions (H+) and bicarbonate ions (HCO3-). The bicarbonate ions are then reabsorbed into the bloodstream, while the hydrogen ions are excreted in the urine. When acetazolamide inhibits carbonic anhydrase, it reduces the reabsorption of bicarbonate ions in the PCT. As a result, more bicarbonate ions are excreted in the urine, leading to a decrease in the concentration of bicarbonate ions in the blood. This decrease in bicarbonate ions is accompanied by an increase in the concentration of chloride ions, which are reabsorbed in the distal convoluted tubule (DCT) to maintain electroneutrality. The resulting metabolic acidosis is characterized by a normal anion gap, as the decrease in bicarbonate ions is matched by an increase in chloride ions. This type of metabolic acidosis is known as renal tubular acidosis type 2 (RTA type 2), also known as proximal RTA. It is characterized by a defect in the reabsorption of bicarbonate ions in the PCT, leading to a hyperchloremic metabolic acidosis. Acetazolamide is a classic cause of RTA type 2, as it inhibits the reabsorption of bicarbonate ions in the PCT.

Answer 43

The correct answer is Bartter’s syndrome. This patient has a hypochloraemic alkalosis, with high urinary sodium, potassium loss and a markedly elevated urinary calcium excretion consistent with the diagnosis of Bartter’s syndrome. Bartter’s syndrome is a rare, autosomal recessive disorder, caused by one of three mutations of the ion transporter or ion channel present in the thick ascending limb of the distal nephron. Type I and II mutations present in infancy (often following premature birth and polyhydramnios) with severe dehydration, hypokalaemic alkalosis, hypercalciuria and nephrocalcinosis. Mortality is high. Type III mutations present with a more varied clinical picture to type I and II, ranging in severity from near fatal volume depletion with hypokalaemic alkalosis and respiratory arrest, to mild disease presenting in teenagers with weakness and polyuria. Nephrocalcinosis has not been described in type III mutations, therefore it can differentiate between type I and II disease, and type III disease. Management is with long term potassium supplementation and care to avoid dehydration. The long term prognosis is uncertain. Laxative abuse tends to cause low urinary sodium and potassium, with low serum bicarbonate, due to GI losses. Thiazide diuretic abuse would fit with the serum findings, but the urinary sodium and potassium is normal (as water will follow the electrolytes). Liddle’s syndrome is a congenital form of salt-sensitive hypertension characterised by a very high rate of renal sodium uptake, despite low levels of aldosterone, secondary hypokalaemia and metabolic acidosis. It is caused by a congenital mutation, which causes a constitutive hyper reactivity in the epithelial sodium channel (ENaC). The increased sodium uptake is accompanied by an increased water uptake, leading to an increase in blood volume, and secondary hypertension. Addison’s disease is primary adrenal insufficiency. The most common cause in the western world is autoimmune adrenalitis, and worldwide causes include TB, fungal infections (histoplasmosis, cryptococcus) and cytomegalovirus. Patients with Addison’s disease have glucocorticoid and mineralocorticoid deficiency. This leads to hypotension, hyponatraemia (in 90%) and hyperkalaemia (in 65%).

Answer 44

The correct answer is Renal tubular acidosis. The laboratory results suggest a metabolic acidosis. Let’s analyze the findings: Low Serum Bicarbonate (HCO3): The serum bicarbonate is below the normal range, indicating a metabolic acidosis. Low Venous pH: The pH is below the normal range, further confirming metabolic acidosis. Elevated Serum Chloride: The elevated chloride is consistent with hyperchloremic metabolic acidosis. Elevated Serum Potassium: The elevated potassium level may be a clue to the cause of the metabolic acidosis. Next, calculate the anion gap = Na – (Bicarb + Cl) = 130 – (14+ 115) = 1 mEq/L Therefore, this is a Non-Anion Gap Metabolic Acidosis (NAGMA) Common causes of NAGMA: Normal saline infusion Resolving diabetic ketoacidosis Gastrointestinal bicarbonate loss Diarrhea (especially secretory) High-output fistulas, pancreatic/biliary drainage Ureteroileostomy or ureterosigmoidostomy Renal insufficiency (typically when GFR is between 20-50 ml/min) Exogenous acid (e.g. total parenteral nutrition, calcium chloride) Chronic hyperventilation (extremely rare) Renal tubular acidosis (RTA) Given the elevated serum potassium and the presence of non-anion-gap metabolic acidosis, the most likely cause is hyperkalemic renal tubular acidosis (RTA). In hyperkalemic RTA, there is impaired acid secretion in the distal tubules, leading to reduced hydrogen ion excretion and impaired ammonium production. This results in a hyperchloremic metabolic acidosis with a normal anion gap. The elevated potassium is also a key feature of hyperkalemic RTA. As the kidneys fail to excrete hydrogen ions, they also fail to excrete potassium, leading to hyperkalemia. The other options are High Anion Gap Metabolic Acidosis (HAGMA): Acute renal failure, Lactic acidosis, Salicylate poisoning and Diabetic Ketoacidosis. Memory Tip: Non-Anion Gap Metabolic Acidosis (NAGMA): use the mnemonic- HARDUPS Hyperalimentation Acetazolamide Renal Tubular Acidosis Diarrhea Uretero-Pelvic Shunt Post-Hypocapnia Spironolactone High Anion Gap Metabolic Acidosis (HAGMA): use the mnemonic- MUDPILERS Methanol Uremia DKA/Alcoholic KA Paraldehyde Isoniazid Lactic Acidosis Ethanol/Ethylene Glycol Rhabdo/Renal Failure Salicylates

Answer 45

The correct answer is secreted by the tubules. As glomerular filtration rate (GFR) declines, urinary creatinine clearance tends to overestimate GFR because creatinine is both filtered at the glomerulus and secreted by the renal tubules. Creatinine is a byproduct of muscle metabolism and is freely filtered by the glomerulus into the renal tubules. However, a fraction of creatinine is also actively secreted by the renal tubules into the urine. In individuals with reduced GFR, there is less creatinine filtered at the glomerulus, but the tubular secretion of creatinine may remain relatively unchanged. This leads to a situation where the creatinine clearance, calculated based on the urinary excretion of creatinine, overestimates the actual GFR. To more accurately estimate GFR, other markers such as cystatin C or equations that take into account both serum creatinine and factors like age, gender, and race (e.g., the Modification of Diet in Renal Disease, MDRD, or Chronic Kidney Disease Epidemiology Collaboration, CKD-EPI, equations) are often used. These equations are designed to correct for the limitations of using creatinine alone as a marker of kidney function, especially when GFR is significantly reduced.

Answer 46

ANSWER - ATN - Note - drugs normally cause AIN... but this is where people trip up - Gentamicin is a big exception to the rule >:/ *** The correct answer is acute tubular necrosis. Acute renal failure as a result of gentamicin use most frequently results from acute tubular necrosis (ATN). Gentamicin, an aminoglycoside antibiotic, is known for its nephrotoxic potential, which can lead to acute kidney injury (AKI). The primary mechanism of gentamicin-induced AKI is related to its accumulation in the renal cortex, particularly within the proximal tubular cells. This accumulation can lead to cellular damage and necrosis, primarily affecting the tubular epithelium. The nephrotoxicity associated with gentamicin and other aminoglycosides is characterized by a decrease in renal function, which can be observed as an increase in serum creatinine and blood urea nitrogen (BUN) levels. The tubular damage can also lead to nonoliguric renal failure, where urine output is not severely affected initially. Other mechanisms listed, such as cast nephropathy, focal segmental glomerulosclerosis, proliferative glomerulosclerosis, and interstitial nephritis, are not typically associated with gentamicin-induced renal injury. Interstitial nephritis, for example, is more commonly associated with other medications like NSAIDs, certain antibiotics like penicillins and cephalosporins, and proton pump inhibitors, rather than aminoglycosides like gentamicin. Acute interstitial nephritis (often with tubular damage): Allopurinol Antivirals (indinavir, atazanavir, adefovir, tenofovir, abacavir) Cephalosporins Cimetidine Phenytoin Diuretics Non-steroidal anti-inflammatory drugs Penicillins Proton pump inhibitor Rifampicin Sulphinpyrazone Sulphonamides Acute Tubular necrosis: Aminoglycosides Amphotericin B Cephalosporins Cisplatin Co-trimoxazole Cyclosporine Lithium Methyldopa Radiographic contrast media Obstructive uropathy: Papillary necrosis Analgesics Antivirals (indinavir) Urate obstruction Cytotoxic drugs Intratubular crystal obstruction Sulphonamides (sulphadiazine) Antivirals (acyclovir, indinavir) Periureteric fibrosis Methysergide Renal vasculitis Amphetamines Penicillins Sulphonamides Intrarenal hemodynamic changes Afferent arteriolar vasoconstriction Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, cyclosporine, tacrolimus Efferent arteriolar vasoconstriction ACEIs and ARBs Hypercatabolism Tetracyclines

Answer 47

The correct answer is Aspirin Drugs that have low molecular weights, are water-soluble, and have low protein binding are more likely to be effectively cleared by dialysis. Some examples of drugs that may be cleared by dialysis: 1. Lithium: Lithium is a mood-stabilizing medication used in the treatment of bipolar disorder. It has a low molecular weight and is water-soluble, making it amenable to clearance by dialysis. 2. Ethanol (Alcohol): Ethanol, or alcohol, is water-soluble and has a low molecular weight, allowing it to be removed by dialysis. In cases of severe alcohol intoxication, hemodialysis may be employed to enhance ethanol clearance. 3. Methanol and Ethylene Glycol: These are toxic alcohols that can be found in certain industrial products. In cases of poisoning, hemodialysis is often used to enhance the elimination of these substances. 4. Salicylates (Aspirin): Salicylates, such as aspirin, have a relatively low molecular weight and are water-soluble. In cases of severe salicylate toxicity, hemodialysis can be employed to enhance elimination. 5. Aminoglycoside Antibiotics: Some aminoglycoside antibiotics, such as gentamicin and tobramycin, have low molecular weights and can be cleared by dialysis. However, their clearance is not as efficient as other smaller molecules. 6. Theophylline: Theophylline, used in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), has a low molecular weight and can be removed by dialysis in cases of toxicity. Memory Tip: Drugs that can be cleared by hemodialysis: “BLAST” Barbiturate Lithium Alcohol (methanol,ethylene glycol) Salicylates Theophyllines

Answer 48

The correct answer is Conn’s syndrome. The clinical presentation of a 50-year-old man with hypertension, hypokalemia (low serum potassium), and an elevated plasma aldosterone concentration suggests the possibility of primary hyperaldosteronism, specifically aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia. Let’s analyze the key findings: 1. Hypertension: The elevated blood pressure is a common feature of primary hyperaldosteronism. 2. Hypokalemia: The low serum potassium level is a characteristic finding in primary hyperaldosteronism, as aldosterone increases potassium excretion in the urine. 3. Normal Serum Sodium and Creatinine: These are within the normal range, but the focus here is on the potassium and aldosterone levels. 4. Urinary Potassium: The urinary potassium concentration is elevated, consistent with increased excretion due to aldosterone-induced potassium wasting. 5. Plasma Renin: The plasma renin level is suppressed. In primary hyperaldosteronism, the renin-angiotensin-aldosterone system is usually suppressed because the elevated aldosterone levels suppress renin release. 6. Plasma Aldosterone: The elevated plasma aldosterone concentration supports the diagnosis of primary hyperaldosteronism. Given these findings, the most likely diagnosis in this case is primary hyperaldosteronism, and further differentiation between aldosterone-producing adenoma (APA) and bilateral adrenal hyperplasia would typically involve imaging studies (such as adrenal CT or MRI) and adrenal vein sampling

Answer 49

This one is sneaky but elegant — examiners LOVE it 🧠 Mechanism of licorice-associated hypertension The one-liner (memorise this) ***Licorice inhibits 11β-hydroxysteroid dehydrogenase type 2, allowing cortisol to activate mineralocorticoid receptors → apparent hyperaldosteronism.*** Step-by-step (simple brain version) 1️⃣ What normally protects the kidney In the distal nephron, mineralocorticoid receptors (MRs) are meant to respond to aldosterone BUT cortisol circulates at much higher levels than aldosterone So the kidney uses an enzyme: 11β-HSD2 Converts cortisol → cortisone (inactive at MR) 🧠 Think: 11β-HSD2 = the kidney’s bouncer 2️⃣ What licorice does Licorice contains glycyrrhetinic acid This inhibits 11β-HSD2 Result: Cortisol is NOT inactivated Cortisol floods the MR 3️⃣ What happens next Cortisol now acts like aldosterone → ↑ Sodium reabsorption → hypertension ↑ Potassium secretion → hypokalaemia Volume expansion → renin suppressed Aldosterone also suppressed 👉 Looks like hyperaldosteronism, but aldosterone is low Lab pattern (VERY high yield) Test Result BP High K⁺ Low Renin Low Aldosterone Low Cause Cortisol acting as aldosterone 🧠 This is called Apparent Mineralocorticoid Excess (AME) Key exam contrast (Conn vs licorice) Feature Conn’s Licorice Aldosterone High Low Renin Low Low Mechanism Aldosterone excess Cortisol excess at MR Cause Adrenal Enzyme inhibition Where this shows up IRL Licorice lollies 🍬 Herbal teas Traditional medicines Sometimes chewing tobacco Ultra-sticky memory hook Licorice “turns off the cortisol off-switch” Cortisol sneaks into aldosterone’s seat Kidney can’t tell the difference → chaos EXAM ONE-LINER - Licorice causes HTN by inhibiting 11β-hydroxysteroid dehydrogenase type 2, resulting in cortisol-mediated mineralocorticoid receptor activation with low renin and low aldosterone

Answer 50

The correct answer is (A) - plasma aldosterone after four hours of saline infusion. Suspected diagnosis is primary aldosteronism. Aldosterone to renin ratio is the commonest screening test. If PAC/PRA ratio >30 + PAC of >555pmol/L, sensitivity and specificity for primary aldosteronism is 90%. Confirm the diagnosis by doing either one of the following tests: 1) 3 days of oral saline loading -potassium must be normal.urinary aldosterone excretion is then measured. 2) IV NaCl loading 2L over 4 hours (most commonly used) 3) 3 days of oral fludrocortisone suppression 4) Captopril challenge Aim is to look for suppression of aldosterone. Causes of primary aldosteronism: bilateral adrenal hyperplasia (most common) adrenal adenoma familial hyperaldosteronism unilateral adrenal hyperplasia adrenal carcinoma ectopic aldosterone production(rare) Subsequent work up: 1) If suspecting familial hyperaldosteronism (+ve family Hx,Early onset HT and family Hx of hemorrhagic CVA before age 40), then test for the Hybrid gene. 2) If negative for Hybrid gene, could this be a unilateral or bilateral adrenal hyperplasia? Perform adrenal CT to find out. If lesion >4cm it is likely a carcinoma If lesion is 1cm or less then it is likely to be an adenoma. But CT cannot distinguish between aldosterone producing and non functioning nodules. So perform an adrenal venous sampling to determine if it is a bilateral or unilateral PAH.Cortisol Corrected ratio: >4 = unilateral adenoma.

Answer 51

B - Barbiturates L - Lithium A - Alcohol S - Salicylates (aspirin) T - Theophylline So like... not that many :/

Answer 52

The correct answer is spironolactone. Spironolactone can lead to falsely elevated aldosterone levels in blood tests. This is because the medication competes with aldosterone for binding to mineralocorticoid receptors. When assessing aldosterone levels, it’s advisable to discontinue spironolactone for a certain period before testing to obtain more accurate results. Spironolactone can also increase plasma renin activity. Since the renin-angiotensin-aldosterone system is suppressed in Conn’s syndrome, an elevated PRA might suggest primary hyperaldosteronism. However, if the patient is already on spironolactone, this can complicate the interpretation of renin levels. Enalapril is an ACE inhibitor, which reduces the production of angiotensin II, thereby decreasing aldosterone secretion and potentially increasing plasma renin activity. While it can affect the renin-angiotensin-aldosterone system, it does not directly interfere with the aldosterone:renin ratio as significantly as spironolactone. Spironolactone directly blocks aldosterone receptors, making it more likely to skew the ratio results used to diagnose primary hyperaldosteronism. Drugs that stimulate renin secretion (produces false negative): Spironolactone ACE inhibitors ARBs Diuretics Dihydropyridine calcium channel antagonist Drugs that suppress renin levels (produces false positive): Alpha-methyldopa Beta-blockers Clonidine Diclofenac(NSAIDs). Diuretics (including spironolactone)- withhold for at least 6 weeks. Other interfering meds- withhold for at least 2-4 weeks. Consider using oral verapamil , hydralazine or prazosin to maintain hypertension control while the above medications are withheld.

Answer 53

The correct answer is Hypokalemia In a patient with primary aldosteronism secondary to a unilateral adrenal hyperplasia undergoing adrenalectomy, the biochemistry marker that is most likely to improve post-surgery is the serum potassium level. Primary aldosteronism is characterized by excessive production of aldosterone, leading to increased sodium reabsorption and potassium excretion in the kidneys. This results in hypertension, hypokalemia (low serum potassium), and metabolic alkalosis. When a patient with primary aldosteronism undergoes adrenalectomy to remove the adrenal gland responsible for excessive aldosterone production (in this case, due to unilateral adrenal hyperplasia), the remaining adrenal gland and the body’s overall aldosterone production should decrease. As a result, there is a reduced effect on sodium and potassium balance. The improvement in potassium balance is particularly notable. Since aldosterone is a hormone that increases the excretion of potassium in the urine, the removal of the source of excess aldosterone production (in this case, the adrenal gland with hyperplasia) helps normalize potassium levels. Therefore, post-surgery, the patient is likely to experience an improvement in serum potassium levels. It’s important to note that blood pressure may also improve after surgery, and other markers such as renin and aldosterone levels may decrease as well.

Answer 54

The answer is Eat more vegetables such as spinach and rhubarb. Foods like spinach, rhubarb, nuts, and wheat bran contains high amount of oxalate and therefore should be avoided. People can help prevent kidney stones by making changes in their fluid intake. Drinking enough fluids each day is the best way to help prevent most types of kidney stones. Depending on the type of kidney stone a person has, changes in the amounts of sodium, animal protein, calcium, and oxalate consumed can also help. Specific to calcium oxalate stones, a patient should be advised to: reduce sodium intake reduce animal protein, such as meat, eggs, and fish get enough calcium from food or take calcium supplements with food avoid foods high in oxalate, such as spinach, rhubarb, nuts, and wheat bran

Answer 55

The correct answer is Proximal convoluted tubule. The main site of sodium reabsorption in the nephron is the renal tubules, specifically the proximal convoluted tubule (PCT) and the loop of Henle. 1. Proximal Convoluted Tubule (PCT): The majority of sodium reabsorption occurs in the PCT, which is the first segment of the renal tubule. Here, about 65-70% of filtered sodium is reabsorbed. Sodium is reabsorbed through both active and passive processes, involving various transporters on the apical and basolateral membranes of the tubular cells. 2. Loop of Henle: The loop of Henle, particularly the thick ascending limb, is another important site of sodium reabsorption. In this segment, sodium is actively reabsorbed through the Na-K-2Cl cotransporter (NKCC2) on the apical membrane of the tubular cells. Sodium reabsorption is a crucial process in maintaining fluid and electrolyte balance, blood pressure, and osmotic equilibrium in the body. The remaining segments of the nephron, including the distal convoluted tubule (DCT) and the collecting ducts, also contribute to sodium reabsorption, but to a lesser extent compared to the PCT and loop of Henle. The regulation of sodium reabsorption is tightly controlled by various hormones, such as aldosterone and antidiuretic hormone (ADH), to maintain overall body homeostasis.

Answer 56

The correct answer is Proximal convoluted tubule. Acetazolamide is a medication that belongs to a class of drugs known as carbonic anhydrase inhibitors. The primary site of action for acetazolamide is the proximal convoluted tubule (PCT) in the kidneys. In the renal tubules, particularly in the PCT, carbonic anhydrase is an enzyme that plays a role in the reabsorption of bicarbonate ions. By inhibiting carbonic anhydrase, acetazolamide interferes with the reabsorption of bicarbonate and causes an increase in the excretion of bicarbonate in the urine. The inhibition of carbonic anhydrase by acetazolamide leads to the following effects: 1. Increased Excretion of Bicarbonate: The drug causes an increase in the excretion of bicarbonate in the urine, leading to a metabolic acidosis. 2. Diuresis: Acetazolamide also has a mild diuretic effect, as increased excretion of bicarbonate is associated with increased excretion of sodium and water. Due to its effects on bicarbonate reabsorption, acetazolamide is used for various medical conditions, including the treatment of glaucoma (by reducing intraocular pressure), the prevention of altitude sickness, and as an adjunctive therapy in certain types of epilepsy. The renal effects of acetazolamide can be particularly useful in conditions where the modulation of bicarbonate and electrolyte balance is desired. Summary of medications and their site of action: Acetazolamide– proximal convoluted tubule Frusemide– thick ascending loop of Henle Thiazide, Metolazone, Indapamide– Distal convoluted tubule Spironolactone– collecting duct Amiloride– distal convoluted tubules, connecting tubules, and collecting ducts Triamterene– Collecting tubule

Answer 57

The correct answer is Triamterene Lithium is reabsorbed in the proximal tubule and Lithium absorption follows sodium uptake. Therefore there is increased risk of toxicity with use of diuretics and in state of hypovolemia (Lithium toxicity is compounded by sodium depletion.) Diuretics that act at the distal renal tubule(hydrochlorothiazide, spironolactone, triamterene) increases blood concentrations of lithium. Diuretics that act at the proximal tubule, Acetazolamide reduces blood concentrations of lithium. Interactions that may INCREASE lithium concentrations: Selective Serotonin Re-uptake Inhibitors (SSRIs) Metronidazole Tetracyclines Topiramate Non-steroidal anti-inflammatory drugs (NSAID) ACE inhibitors Thiazide diuretics (may cause a paradoxical antidiuretic effect resulting in possible water retention and lithium intoxication) Spironolactone Frusemide Angiotensin-II receptor antagonists Other drugs affecting electrolyte balance may alter lithium excretion, e.g. steroids Interactions that may DECREASE lithium concentrations: Xanthines (theophylline, caffeine) Sodium bicarbonate and Sodium Chloride containing products Psyllium or Ispaghula husk Urea Mannitol Acetazolamide

Answer 58

The correct answer is Na-K-Cl co-transporter (NKCC2) Frusemide is a loop diuretic that acts on the kidneys to increase the excretion of sodium, chloride, and water. It primarily works by inhibiting the sodium-potassium-chloride co-transporter (NKCC2) in the thick ascending limb of the loop of Henle. The NKCC2 co-transporter is responsible for actively transporting sodium, potassium, and chloride ions from the tubular fluid into the cells of the renal tubules. By inhibiting NKCC2, furosemide disrupts this active transport process, leading to increased excretion of sodium, chloride, and water in the urine. This diuretic effect is beneficial in conditions where reducing fluid retention is desired, such as in heart failure, edema, and hypertension.

Answer 59

The correct answer is B,C,E,D,A The renin-angiotensin system (RAS) is a hormonal system that plays a crucial role in regulating blood pressure and fluid balance in the body. Here is the correct order of events in the renin-angiotensin system in response to low blood pressure: 1. Low Blood Pressure (Hypotension): The system is activated in response to low blood pressure or reduced blood flow to the kidneys. 2. Renin Release: Specialized cells in the kidneys, called juxtaglomerular cells, release the enzyme renin into the bloodstream in response to signals of low blood pressure. 3. Angiotensinogen Conversion: Renin acts on angiotensinogen, a precursor protein produced by the liver, converting it into angiotensin I. This conversion takes place in the bloodstream. 4. Angiotensin I to Angiotensin II Conversion: Angiotensin I is then converted to its active form, angiotensin II, by the angiotensin-converting enzyme (ACE). This conversion primarily occurs in the lungs, but ACE is also found in other tissues. 5. Angiotensin II Actions: -Vasoconstriction: Angiotensin II causes blood vessels to constrict, leading to an increase in blood pressure. – Stimulation of Aldosterone Release: Angiotensin II stimulates the release of aldosterone from the adrenal glands. Aldosterone acts on the kidneys to increase the reabsorption of sodium and water, leading to an expansion of blood volume. – Antidiuretic Hormone (ADH) Release: Angiotensin II stimulates the release of ADH (vasopressin) from the posterior pituitary. ADH enhances water reabsorption in the kidneys, contributing to increased blood volume. 6. Blood Pressure Increase: The combined effects of vasoconstriction, increased blood volume, and increased cardiac output contribute to a rise in blood pressure, helping to restore blood pressure to normal levels. This system is a critical regulatory mechanism for maintaining blood pressure and fluid balance in the body. It plays a key role in responding to changes in blood pressure and ensuring that organs, especially the kidneys, receive adequate perfusion.

Answer 60

The correct answer is Gitelman’s syndrome The clinical presentation and laboratory findings suggest the possibility of Gitelman syndrome, which is an inherited renal tubular disorder characterized by hypokalemia, metabolic alkalosis, hypomagnesemia, and hypocalciuria. Key findings in Gitelman syndrome include: 1. Hypokalemia: Low serum potassium levels. 2. Metabolic Alkalosis: Elevated serum bicarbonate levels, indicating an acid-base disturbance. 3. Hypomagnesemia: Low serum magnesium levels. 4. Hypocalciuria: Decreased calcium excretion in the urine. In the above case, the low potassium (2.4 mmol/L), elevated bicarbonate (32 mmol/L), low magnesium (0.35 mmol/L), and the urine electrolyte pattern (urine sodium 60 mmol/L, urine potassium 50 mmol/L, urine chloride 100 mmol/L) are consistent with Gitelman syndrome. Gitelman syndrome is an autosomal recessive disorder caused by mutations in the SLC12A3 gene, which encodes the thiazide-sensitive sodium-chloride cotransporter (NCC) in the distal convoluted tubule of the kidney. This leads to impaired reabsorption of sodium and chloride in the distal tubule, resulting in electrolyte imbalances. It’s important to note that Gitelman syndrome typically presents in late childhood or adolescence, and affected individuals may be asymptomatic or present with weakness, fatigue, or muscle cramps. Genetic testing can confirm the diagnosis, and management often involves the supplementation of potassium and magnesium, along with a high-potassium diet. STEP BY STEP APPROACH: 1) Is the patient normotensive or hypertensive? Only Bartter’s and Gittleman’s would be normotensive. 2) Is the patient acidotic or alkalotic? Only Gordon’s syndrome cause metabolic acidosis. The rest causes metabolic alkalosis. 3) If normotensive, check the urine prostaglandin E. Urine prostaglandin E is elevated in Bartter’s but normal in Gittleman’s. 1 B-HSD= 11B-hydroxysteroid dehydrogenase.(AME presentation similar to licorice and Liddle’s)

Answer 61

The correct answer is Proximal convoluted tubule. Acetazolamide is a medication that belongs to a class of drugs known as carbonic anhydrase inhibitors. The primary site of action for acetazolamide is the proximal convoluted tubule (PCT) in the kidneys. In the renal tubules, particularly in the PCT, carbonic anhydrase is an enzyme that plays a role in the reabsorption of bicarbonate ions. By inhibiting carbonic anhydrase, acetazolamide interferes with the reabsorption of bicarbonate and causes an increase in the excretion of bicarbonate in the urine. The inhibition of carbonic anhydrase by acetazolamide leads to the following effects: 1. Increased Excretion of Bicarbonate: The drug causes an increase in the excretion of bicarbonate in the urine, leading to a metabolic acidosis. 2. Diuresis: Acetazolamide also has a mild diuretic effect, as increased excretion of bicarbonate is associated with increased excretion of sodium and water. Due to its effects on bicarbonate reabsorption, acetazolamide is used for various medical conditions, including the treatment of glaucoma (by reducing intraocular pressure), the prevention of altitude sickness, and as an adjunctive therapy in certain types of epilepsy. The renal effects of acetazolamide can be particularly useful in conditions where the modulation of bicarbonate and electrolyte balance is desired. Summary of medications and their site of action: Acetazolamide– proximal convoluted tubule Frusemide– thick ascending loop of Henle Thiazide, Metolazone, Indapamide– Distal convoluted tubule Spironolactone– collecting duct Amiloride– distal convoluted tubules, connecting tubules, and collecting ducts Triamterene– Collecting tubule

Answer 62

The correct answer is intravenous iron infusion. The laboratory results indicate that the patient has anemia with a low hemoglobin level, and the iron studies show a low transferrin saturation, suggesting iron deficiency. Given the context of end-stage renal failure and hemodialysis, the most appropriate treatment for anemia in this patient is intravenous iron supplementation. Here’s why: Hemodialysis-Related Anemia: Patients on chronic hemodialysis often experience anemia due to various factors, including decreased production of erythropoietin by the failing kidneys. Iron Deficiency: The low transferrin saturation suggests inadequate iron availability, which is a common cause of anemia, especially in individuals undergoing hemodialysis. Intravenous Iron Supplementation: In patients with end-stage renal failure on hemodialysis, oral iron supplements are often less effective due to gastrointestinal absorption issues. Therefore, intravenous iron is frequently preferred for more efficient iron repletion. Considering the low transferrin saturation and the need for effective iron replacement, intravenous iron supplementation, such as iron sucrose or ferric carboxymaltose, would be a suitable choice. The goal is to improve iron stores, enhance erythropoiesis, and address the anemia in the context of chronic kidney disease and hemodialysis. Targets for ferritin and transferrin saturations in ESRF patients: Ferritin >200 Transferrin saturation > 20%. The demand for iron by the bone marrow is enormous when erythropoietin is commenced. Patients on EPO therapy are regularly monitored for iron status and considered iron deficient if plasma ferritin is < 100 μg/L, hypochromic RBCs > 10%, transferrin saturation < 20%. Once erythropoeitin is commenced, blood pressure, haemoglobin concentration and reticulocyte count are measured every 2 weeks and the dose adjusted to maintain a target haemoglobin of 120-130 g/L (Australian guidelines)

Answer 63

The correct answer is Peritubular cells Erythropoietin (EPO) is predominantly produced by specialized cells called peritubular interstitial cells, which are located in the peritubular capillaries of the renal cortex and outer medulla of the kidneys. These cells are also known as interstitial fibroblasts or type I interstitial cells. They play a crucial role in the regulation of erythropoiesis by releasing erythropoietin in response to low oxygen levels in the blood. When oxygen levels in the blood are low, as sensed by the kidneys, these peritubular interstitial cells release erythropoietin into the bloodstream. Erythropoietin then travels to the bone marrow, where it stimulates the production of red blood cells by promoting the differentiation and maturation of erythroid progenitor cells. This feedback mechanism is essential for maintaining the appropriate oxygen-carrying capacity of the blood and ensuring adequate oxygen delivery to tissues and organs throughout the body. Functions of cell in the kidney: Parenchymal cells of the kidney are those that make up the nephrons Principal cells are predominantly responsible for sodium reabsorption and potassium secretion in the kidney. Intercalated cell in the collecting duct, consists of two types: The Alpha intercalated cell is responsible for secreting excess Acid and reabsorbing base (in the form of bicarbonate). The Beta intercalated cell is responsible for secreting excess Base (bicarbonate) and reabsorbing acid 4. Peritubular cells makes Erythropoietin

Answer 64

The correct answer is inflammation. The information provided suggests that the patient is experiencing erythropoietin resistance, which means that despite receiving erythropoietin, her hemoglobin level is lower than expected. In this case, several factors can contribute to erythropoietin resistance, and the given laboratory values offer some insights. The most likely cause for erythropoietin resistance in this patient is iron deficiency. Let’s analyze the given information: 1. Low Hemoglobin (Hb): – The patient’s Hb level has decreased from the previous range (105-115 gm/L) to 89 gm/L. 2. Normal Mean Corpuscular Volume (MCV): – The MCV is within the normal range (84 fL), suggesting that the red blood cells are not macrocytic (enlarged). 3. Low Serum Iron (13 micromol/l): – The serum iron level is low, indicating insufficient iron availability. 4. Low Iron Saturation (18%): – Iron saturation is below the normal range, supporting the evidence of decreased iron availability for erythropoiesis. 5. High Serum Ferritin (630 microg/l): – The serum ferritin level is elevated, which may seem contradictory at first. However, in the context of chronic kidney disease and inflammation, ferritin levels can be elevated even in the presence of functional iron deficiency. 6. Increased Reticulocyte Count (30 x 10^9/L): – The reticulocyte count is elevated, indicating an appropriate bone marrow response to anemia but suggesting that iron availability might be limiting erythropoiesis. Based on these findings, the most likely cause of erythropoietin resistance in this patient is functional iron deficiency due to inflammation. In chronic kidney disease, inflammation and hepcidin-mediated iron sequestration can contribute to functional iron deficiency, even when serum ferritin levels are high. Addressing iron deficiency, either by adjusting iron supplementation or investigating and treating potential causes of inflammation, may help improve the response to erythropoietin therapy. Causes of erythropoeitin failure: 1) iron deficiency. Clues to diagnosis: plasma ferritin is < 100 μg/L, hypochromic RBCs > 10%, transferrin saturation < 20%. 2) bleeding- look at the history. 3) malignancy- look at the history. 4) infection – look at the history. high ferritin. 5) inflammation – functional iron deficiency due to poor mobilization of iron, despite adequate iron stores. Clues to diagnosis: ferritin > 500 μg/L and a transferrin saturation of > 20%. Caused by hepcidin. 6) formation of anti-EPO neutralizing antibodies resulting in pure red cell aplasia. Clues to diagnosis: low or no reticulocytes.

Answer 65

Answer - A - EPO for anaemia This is such a bullshitty question The kidneys are O2 hungry organs and hypoxia / anaemia absolutely causes worsening renal function :/ BUT EPO only makes the patient feel better, it does not actually slow CKD progression (which is the question)... and if you think about it, we had to stop aiming for normal Hb targets in CKD patients because of the increased risk of thrombosis and stroke! *** The correct answer is correction of anemia using erythropoietin. While EPO can address anemia, it does not directly impact the progression of renal failure or the underlying cause of glomerulonephritis. EPO is more focused on managing anemia-related symptoms and improving quality of life rather than altering the course of the kidney disease itself. Advantages of erythropoietin: 1) improves quality of life 2) improves exercise tolerance 3) improves sexual function 4) improves cognitive function in dialysis patients 5) leads to regression of left ventricular hypertrophy. Disadvantages of erythropoietin therapy: 1) expensive 2) hypertension or worsening of HT(main side effect) 3) Increase peripheral resistance due to loss of hypoxic vasodilatation and to increased blood viscosity. 4) encephalopathy (rare)

Answer 66

The correct answer is decreased production of erythropoeitin. The predominant cause of anemia in chronic renal failure is a deficiency of erythropoietin (EPO). Erythropoietin is a hormone produced by the kidneys, and its primary role is to stimulate the production of red blood cells in the bone marrow. In chronic renal failure, the kidneys are unable to produce an adequate amount of erythropoietin due to the loss of nephrons and overall kidney function. The reduction in erythropoietin levels leads to a decrease in the production of red blood cells, resulting in anemia. Anemia in CKD is often referred to as “renal anemia” or “anemia of chronic kidney disease.” Key factors contributing to anemia in chronic renal failure include: 1. Erythropoietin Deficiency: The impaired production of erythropoietin by the diseased kidneys results in insufficient stimulation of red blood cell production. 2. Decreased Iron Availability: Chronic kidney disease can affect iron metabolism, leading to decreased iron availability for red blood cell synthesis. Iron is a crucial component for hemoglobin, the protein in red blood cells that carries oxygen. 3. Shortened Red Blood Cell Lifespan: Kidney disease can contribute to the shortening of red blood cell lifespan, further contributing to anemia. The management of anemia in chronic renal failure often involves the administration of erythropoietin-stimulating agents (ESAs) to stimulate red blood cell production. Additionally, iron supplementation may be necessary to address iron deficiency and optimize the response to ESAs.

Answer 67

The correct answer is type 1 diabetes without diabetic nephropathy. The patient’s clinical presentation and laboratory findings point towards the diagnosis of Type 1 diabetes mellitus without diabetic nephropathy. This is the most likely diagnosis given the patient’s symptoms of polyuria, polydipsia, and weight loss, along with the significantly elevated blood glucose level which are classic for new-onset Type 1 diabetes mellitus. The lack of significant proteinuria and other renal impairment markers makes the presence of diabetic nephropathy unlikely at this stage. The onset of diabetic nephropathy is less likely given the short duration of symptoms and the absence of significant proteinuria or other markers of renal damage. Diabetic nephropathy typically develops after several years of poorly controlled diabetes. Acute Interstitial Nephritis is a condition that typically presents with symptoms like rash, fever, arthralgia, and renal dysfunction. The patient’s urinalysis shows no eosinophils or casts that are often associated with interstitial nephritis. The clinical presentation and lab results don’t align well with acute interstitial nephritis. Acute Tubular Necrosis (ATN) typically presents with acute kidney injury and is often associated with a history of hypotension, sepsis, or nephrotoxic drugs. The patient’s renal function (as indicated by serum creatinine) is normal, making ATN unlikely. Goodpasture Syndrome is an autoimmune disease, which often presents with pulmonary hemorrhage and glomerulonephritis, is not consistent with this patient’s presentation. The absence of hematuria and other clinical features of Goodpasture syndrome makes this diagnosis unlikely. Therefore, the most likely diagnosis for this patient, given the clinical presentation and laboratory findings, is Type 1 diabetes mellitus without diabetic nephropathy. The presence of hyperglycemia, polyuria, polydipsia, weight loss, and absence of significant renal dysfunction would support this diagnosis.

Answer 68

The correct answer is Immunoglobulin A (IgA) nephropathy. The combination of persistent hematuria, trace proteinuria, and normal blood pressure in this young man may suggest a possible renal glomerular condition. One such condition that needs consideration is IgA nephropathy, also known as Berger’s disease. IgA nephropathy is a form of glomerulonephritis characterized by the deposition of immunoglobulin A (IgA) in the glomeruli of the kidneys. It often presents with recurrent episodes of gross or microscopic hematuria, typically following upper respiratory tract infections. The clinical presentation in this case, with isolated hematuria and minimal proteinuria, along with normal blood pressure and normal serum creatinine, aligns with the early stages of IgA nephropathy. It’s worth noting that IgA nephropathy can vary widely in its clinical course, and some individuals may have mild or no symptoms for an extended period. Further diagnostic evaluation may include a kidney biopsy to confirm the diagnosis and assess the degree of kidney damage. Management strategies for IgA nephropathy involve monitoring for progression, blood pressure control, and addressing potential risk factors such as infections.

Answer 69

The correct answer is mesangiocapillary A persistent reduction of serum complement component 3 (C3) is strongly associated with mesangiocapillary glomerulonephritis (MCGN), also known as membranoproliferative glomerulonephritis (MPGN). MCGN is a type of glomerulonephritis characterized by alterations in the glomerular capillary wall, leading to increased cellularity and changes in the mesangial cells. There are three subtypes of MCGN, and two of them (Type I and Type III) are associated with a persistent reduction in serum C3 levels. The complement system plays a crucial role in the immune response and is involved in the inflammatory process. In MCGN, the complement system is often activated in the glomeruli, leading to the consumption of complement components, including C3. The persistent reduction in serum C3 levels is a result of ongoing complement activation and consumption in the glomeruli. It’s important to note that while a persistent reduction in C3 is a characteristic feature of MCGN, other conditions can also lead to decreased C3 levels. Therefore, a comprehensive evaluation, including clinical history, renal biopsy, and additional laboratory tests, is typically necessary for an accurate diagnosis. If MCGN is suspected, further diagnostic studies such as renal biopsy may be warranted to confirm the diagnosis and guide appropriate management. Here are some differential diagnoses of acute glomerulonephritis which can be divided as follows based on percentages which indicate approximate frequency of C3 or hemolytic complement: Conditions associated with LOW serum complement level: SLE (focal, 75%; diffuse, 90%) Subacute bacterial endocarditis (90%) Visceral abscess “Shunt” nephritis (90%) Cryoglobulinemia (58%)Renal diseases Acute postinfectious glomerulonephritis (>90%) MPGN – Type I (50-80%), type 2 (80-90%) Conditions associated with NORMAL serum complement level: Polyarteritis nodosa group Hypersensitivity vasculitis Wegener granulomatosis HSP Goodpasture syndromeRenal diseases IgA (or IgG-IgA) nephropathy Idiopathic rapidly progressive glomerulonephritis (RPGN) Anti-glomerular basement membrane (GBM) disease Negative immunofluorescence findings Immune complex disease

Answer 70

The correct answer is idiopathic mesangiocapillary glomerulonephritis. The clues to the diagnosis here are the presence of dysmorphic red cells and red cell cast. The clinical presentation of generalized swelling, hypertension, and urinary abnormalities, including significant proteinuria, hematuria with dysmorphic red cells, and casts are all suggestive of an underlying glomerular disease. In this case, the most likely renal pathology is glomerulonephritis with nephrotic range proteinuria. The combination of hypertension, proteinuria, and hematuria with red cell casts is often associated with glomerular involvement. The specific pattern of findings, including dysmorphic red cells and red cell casts, raises the suspicion of mesangiocapillary GN. A kidney biopsy, may be necessary to determine the specific type of glomerulonephritis.

Answer 71

Due to loss of anti-thrombin III in the urine

Answer 72

The correct answer is Granulomatosis with polyangiitis The clinical presentation of hemoptysis, pulmonary consolidation in the right upper lobe and left lower lobe, abnormal renal function with elevated creatinine and proteinuria, bloody rhinorrhea, and a positive cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA) test is highly suggestive of Wegener’s granulomatosis, now known as granulomatosis with polyangiitis (GPA). Granulomatosis with polyangiitis is a systemic vasculitis that primarily affects small- to medium-sized blood vessels. It commonly involves the upper and lower respiratory tracts and the kidneys. The positive c-ANCA test is a characteristic finding in GPA. The pulmonary involvement can lead to symptoms such as hemoptysis and lung consolidations, while renal involvement can cause glomerulonephritis with elevated creatinine and proteinuria. The presence of bloody rhinorrhea further supports the diagnosis, as GPA often affects the upper respiratory tract. It is crucial for this patient to receive prompt and appropriate medical attention from a rheumatologist or nephrologist for further evaluation, confirmation of the diagnosis, and initiation of appropriate treatment, typically involving immunosuppressive therapy. Some pointers on Granulomatosis with polyangiitis: Systemic vasculitis that typically involves small and medium vessels. Classic triad consists of upper and lower respiratory tract involvement and pauciimmune glomerulonephritis. Involvement of cutaneous, ocular, musculoskeletal and peripheral nervous system tissue is also common. Antineutrophil cytoplasmic antibody (ANCA) testing may help with diagnosis, but is not useful for monitoring disease activity. Induction of remission is usually achieved using cyclophosphamide or methotrexate, given in combination with corticosteroids. Remission is maintained using corticosteroids and either azathioprine or methotrexate. Common Lab findings: Urinalysis may show haematuria, proteinuria; dysmorphic red blood cells, RBC casts cANCA positivity CT Chest may show lung nodules or infiltrates Elevated serum Creatinine and ESR Anaemia

Answer 73

The correct answer is Ureterosigmoidostomy. The abnormal electrolyte and laboratory results suggest that the patient may be experiencing metabolic acidosis with hypokalemia. Let’s analyze the findings: 1. Hypokalemia: – Potassium is below the normal range (3.5-5.2 mmol/L). – This can lead to various symptoms, including muscle weakness, fatigue, and abdominal pain. 2. Metabolic Acidosis: – Low bicarbonate (15 mmol/L, normal range 24-28 mmol/L) levels suggest metabolic acidosis. – Metabolic acidosis is a condition where there is a loss of bicarbonate in the body, leading to a reduction in blood pH. 3. Normal Sodium with elevated Chloride: – Sodium is within normal range (142 mmol/L, normal range 138-145 mmol/L). – Chloride is elevated (112 mmol/L). 4. Normal Corrected Calcium and Albumin: – Corrected calcium (2.40 mmol/L, normal range 2.15-2.57 mmol/L) and albumin (42 g/L, normal range 38-48 g/L) are within normal limits. – There is no evidence of calcium or albumin abnormalities. 5. Normal Creatinine: – Creatinine is within normal limits (0.11 mmol/L, normal range 0.5-0.12 mmol/L). Now let’s calculate the anion gap: Na – (Cl+HCO3). In this case, 142 – 127 = 15 (Normal anion gap is 8-15) So the final biochemistry diagnosis is Normal anion gap metabolic acidosis with hypokalemia (Hyperchloremic metabolic acidosis). Hyperchloremic metabolic acidosis is a pathological state that results from bicarbonate loss, rather than acid production or retention. Bicarbonate loss leading to hyperchloremic metabolic acidosis occurs in a variety of ways: gastrointestinal (GI) causes, renal causes, and exogenous causes. GI loss of bicarbonate occurs through severe diarrhea, pancreatic fistula, nasojejunal tube suctioning from the duodenum, and chronic laxative use. Differential diagnoses: 1) Excess Gastrointestinal bicarb loss: diarrhea external pancreatic or small intestine drainage or fistulae Ureterosigmoidostomy, jejunal loop. 2) Renal tubular acidosis Distal RTA (Type 1, Classic) Proximal RTA (Type 2)

Answer 74

The correct answer is distal renal tubular acidosis. The information provided suggests a condition known as distal renal tubular acidosis (dRTA). This is a type of renal tubular acidosis where the kidneys are unable to properly acidify urine, leading to a metabolic acidosis. In this case, the key features include: 1. Metabolic acidosis with hyperchloremia. 2. Normal plasma anion gap. 3. No bicarbonate in the urine. 4. Low urine pH (5.7). The fact that the patient has known Sjogren’s syndrome may be relevant, as dRTA can be associated with autoimmune conditions, including Sjogren’s syndrome. In distal renal tubular acidosis, the distal tubules of the kidneys are unable to secrete hydrogen ions effectively, leading to impaired acidification of urine. This results in an accumulation of acid in the blood, leading to metabolic acidosis. The absence of bicarbonate in the urine and the low urine pH are consistent with the impaired acidification seen in dRTA.

Answer 75

The correct answer is Sjogren syndrome Sjogren’s is the most common autoimmune disorder of Type 1 RTA. Sjogren’s is an autoimmune disorder that is associated with lymphocytic infiltration of exocrine glands that results in decreased tear and saliva production as the most prominent symptoms. Sjögren’s syndrome affects women nine times more frequently than men and usually presents in middle age. Other autoimmune diseases often have associated xerostomia and dry eyes (secondary Sjögren’s syndrome). High titers of antibodies to Ro and La are associated with longer disease duration, salivary gland enlargement, and the development of extraglandular involvement, especially cutaneous vasculitis and demyelinating syndromes. One third of patients with Sjögren’s syndrome have extraglandular involvement of the disease, most commonly in the lungs and kidneys. Interstitial nephritis is a common manifestation of Sjögren’s syndrome in the kidneys. Distal (type I) renal tubular acidosis is also frequent, occurring in 25% of individuals with Sjögren’s syndrome. Diagnosis could be confirmed by obtaining urine electrolytes to demonstrate a positive urine anion gap. Renal biopsy is not necessary. Treatment does not require immunosuppression as the acidemia can be treated with bicarbonate replacement

Answer 76

he correct answer is CKD 3. CKD 3 has the highest prevalence in Australia with 1.4 million people affected based on the AusDiab study. Previously, the chronic kidney disease epidemiology (CKD-EPI) equation used to estimate glomerular filtration rate (GFR) included a term for race such that, for any given age, sex, and serum creatinine, a Black individual would have a higher estimated GFR. The American Society of Nephrology and National Kidney Foundation reevaluated the inclusion of race in estimating GFR and determined that a revised creatinine-based equation (ie, the 2021 CKD-EPI equation) that did not include race was sufficiently accurate for clinical use. This is now the 2021 revised CKD-EPI equation to estimate GFR (calculator 1). The equation applies to people with stable kidney function.

Answer 77

The correct answer is Non-clonal expansion of tubular epithelial cell types In autosomal dominant polycystic kidney disease (ADPKD), which is often associated with mutations in the PKD1 gene (and less commonly in the PKD2 gene), renal cysts develop as a result of abnormal proliferation and differentiation of renal tubular epithelial cells. The key process underlying cyst formation in ADPKD is related to disruptions in the regulation of cell growth and apoptosis (programmed cell death). The mutation in the PKD1 gene, which encodes for the protein polycystin-1, plays a crucial role in the development of cysts. Polycystin-1 is expressed in the primary cilia of renal tubular epithelial cells and functions in signaling pathways that regulate cell proliferation, differentiation, and apoptosis. The loss of functional polycystin-1 leads to dysregulation of these cellular processes, resulting in the following key events: 1. Increased Cell Proliferation: The absence of functional polycystin-1 is associated with increased cell proliferation, leading to the formation of cystic structures. 2. Fluid Secretion: Polycystin-1 is involved in the regulation of ion transport and fluid secretion in the renal tubules. Mutations in PKD1 disrupt these processes, contributing to the accumulation of fluid within the cysts. 3. Cyst Expansion: The abnormal proliferation of cells, coupled with fluid accumulation, causes the cysts to expand over time. 4. Inhibition of Apoptosis: There is evidence that the loss of polycystin-1 may also lead to a resistance to apoptosis (programmed cell death). Normally, cells undergoing abnormal changes would undergo apoptosis as a protective mechanism. In ADPKD, this process may be inhibited, allowing the cysts to persist and grow. The combination of these factors contributes to the formation and expansion of renal cysts in patients with autosomal dominant polycystic kidney disease.

Answer 78

The correct answer is Gitelman’s syndrome Gitelman syndrome is a rare genetic disorder that affects the kidneys’ ability to reabsorb electrolytes, leading to electrolyte imbalances. It is caused by mutations in the SLC12A3 gene, which encodes for a sodium-chloride cotransporter (NCC) in the distal convoluted tubules of the kidneys. The primary characteristic features of Gitelman syndrome include hypokalemia (low potassium levels), hypomagnesemia (low magnesium levels), and metabolic alkalosis. Interestingly, the effects of Gitelman syndrome on electrolyte balance share similarities with the actions of thiazide diuretics, which are a class of medications commonly used to treat conditions such as hypertension and edema. Thiazide diuretics, like hydrochlorothiazide, act on the distal convoluted tubules of the kidneys, similar to the site affected in Gitelman syndrome. Here’s how Gitelman syndrome and thiazide diuretics produce similar effects: 1. Increased Sodium and Chloride Excretion: In Gitelman syndrome, the loss-of-function mutation in the NCC results in reduced reabsorption of sodium and chloride in the distal tubules. Thiazide diuretics also inhibit the NCC, leading to increased excretion of sodium and chloride in the urine. 2. Hypokalemia: Both Gitelman syndrome and thiazide diuretics promote potassium loss. The decreased reabsorption of sodium in the distal tubules creates a favorable environment for increased potassium excretion. This can lead to hypokalemia in both cases. 3. Hypomagnesemia: Gitelman syndrome is characterized by reduced magnesium reabsorption in the distal tubules, resulting in hypomagnesemia. Thiazide diuretics can also cause magnesium wasting, leading to low magnesium levels. 4. Metabolic Alkalosis: The increased excretion of sodium and chloride in the distal tubules, along with the associated potassium and magnesium loss, can lead to metabolic alkalosis in both Gitelman syndrome and thiazide diuretic use. While Gitelman syndrome and thiazide diuretics share some similarities in their effects on electrolyte balance, it’s important to note that the mechanisms causing these imbalances are different. Gitelman syndrome results from a genetic mutation affecting the function of a specific transporter in the kidneys, whereas thiazide diuretics exert their effects pharmacologically by inhibiting the NCC. Management and treatment strategies for Gitelman syndrome and thiazide-induced electrolyte imbalances may differ, and they should be approached based on the underlying cause. Individuals with Gitelman syndrome may require lifelong management to address the electrolyte abnormalities associated with the condition. Memory Tip: Gitelman syndrome = defect in distal tubule = thiazide Bartter’s syndrome = defect in loop of Henle = frusemide Liddle syndrome = increased number Na channel in collecting duct which results in increased sodium reabsorption and potassium excretion. Gordon syndrome = effect is OPPOSITE thiazide or Gitelman’s.

Answer 79

The correct answer is Inhibits purine synthesis Mycophenolate mofetil (MMF) is an immunosuppressive medication commonly used in organ transplantation to prevent rejection. The active form of mycophenolate mofetil is mycophenolic acid (MPA), which inhibits the proliferation of T and B lymphocytes, key cells involved in the immune response. The mechanism of action of mycophenolate mofetil involves the inhibition of the enzyme inosine monophosphate dehydrogenase (IMPDH). Here’s a more detailed explanation: 1. De Novo Purine Synthesis Inhibition: Mycophenolate mofetil specifically inhibits the enzyme IMPDH, which is crucial for the de novo synthesis of guanosine nucleotides (purines). Purines are essential for the synthesis of DNA and RNA, particularly during the proliferation of lymphocytes. 2. Selective Inhibition of Lymphocyte Proliferation: Lymphocytes, especially T and B cells, are highly dependent on the de novo synthesis of purines for their proliferation. By inhibiting IMPDH, mycophenolate mofetil disrupts the production of purines, leading to a reduction in the availability of nucleotides necessary for DNA and RNA synthesis. 3. Cell Cycle Arrest: The inhibition of de novo purine synthesis arrests lymphocytes in the G1 phase of the cell cycle, preventing their progression into the S phase where DNA replication occurs. This halts the proliferation of lymphocytes. 4. Prevention of Immune Response: By suppressing the proliferation of T and B cells, mycophenolate mofetil helps to dampen the overall immune response. This is particularly important in the context of organ transplantation, where the goal is to prevent the recipient’s immune system from attacking and rejecting the transplanted organ. Commonly used immunosuppressive agents in renal transplant

Answer 80

The correct answer is Acute rejection. The rise in serum creatinine levels after a kidney transplant can have various causes. One potential cause in the early post-transplant period is acute rejection. Acute rejection occurs when the recipient’s immune system recognizes the transplanted kidney as foreign and mounts an immune response against it. This immune response can lead to damage and dysfunction of the transplanted organ. In this case, the increase in serum creatinine levels (from 140 μmol/L to 190 μmol/L) suggests a deterioration in kidney function. The normal range for serum creatinine is given as 60 – 120 μmol/L, and the rise in creatinine levels outside this range indicates impaired kidney function. Other potential causes of post-transplant kidney dysfunction should also be considered, such as: 1. Acute Tubular Necrosis (ATN): Ischemic injury to the transplanted kidney during the transplant process or other factors may lead to acute tubular necrosis, causing a temporary decrease in kidney function. 2. Drug-Induced Nephrotoxicity: Certain medications, including immunosuppressive drugs used to prevent rejection (such as calcineurin inhibitors like tacrolimus or cyclosporine), can cause nephrotoxicity and affect kidney function. 3. Infection: Post-transplant infections, particularly urinary tract infections or systemic infections, can impact kidney function. 4. Vascular Complications: Issues such as thrombosis or stenosis of the blood vessels supplying the transplanted kidney can lead to reduced blood flow and impaired function. To determine the specific cause of the decline in kidney function, additional diagnostic tests, such as kidney biopsy, ultrasound, and blood tests, may be necessary. Monitoring for signs of rejection and infections, as well as adjusting immunosuppressive medications, are important aspects of managing post-transplant kidney dysfunction. Types of transplant rejection: 1) Hyperacute rejection: – Rare. Occurs very early and is untreatable. – Due to preformed antibodies. On table black kidney. – Predictable by cytotoxic cross match 2) Acute rejection (up to 25%): – Occurs early but treatable. – T cell mediated vs Antibody mediated – Diagnosis by biopsy Pathology: – T cell mediated: – Cellular/ interstitial- tubulitis, infiltrate.Vascular/glomerular- endothelialitis – Antibody mediated: PMNs, deposition of complement component C4d+ Differential diagnoses: – Volume depletion – ATN – Interstitial nephritis – Drugs: Calcineurin toxicity, Bactrim. – Obstruction – HUS – Infection with CMV, BK virus (beyond 4 weeks) 3) Chronic rejection (30%): – Occurs late. no specific treatment. – Unknown etiology. – Progressive renal dysfunction, proteinuria, hypertension. – Diagnosed clinically from biopsy – DDX: GN, drugs, HT. Management of acute rejection: 1) Obtain tissue diagnosis. 2) IV methylprednisone 500-1000 mg daily for 3 days. 3) Failure to respond is an indication for antibody therapy, usually with OKT3 or antithymocyte depleting antibodies. 4) +/- increase in Calcineurin inhibitor (only if levels subtherapeutic) 5) Plasma exchange, IVIG or Rituximab for antibody mediated rejection. 6) Rescue: Refractory or recurrent rejection- use high dose Tacrolimus or MMF. Practice Points: Clinical evidence of rejection is rarely characterized by fever, swelling, and tenderness over the allograft. Rejection may present only with a rise in serum creatinine, with or without a reduction in urine volume. Diagnostic ultrasound is the procedure of choice to rule out urinary obstruction or to confirm the presence of perirenal collections of urine, blood, or lymph. Diagnosis of rejection is by renal biopsy. Calcineurin inhibitors have an afferent arteriolar constrictor effect on the kidney and may produce permanent vascular and interstitial injury after sustained high-dose therapy. Features to suggest calcineurin inhibitor toxicity include interstitial fibrosis, isometric tubular vacuolization, and thickening of arteriolar walls. Basically, if the biopsy does not reveal moderate and active cellular rejection activity, the serum creatinine will most likely respond to a reduction in dose.

Answer 81

The correct answer is Acute rejection. The rise in serum creatinine levels after a kidney transplant can have various causes. One potential cause in the early post-transplant period is acute rejection. Acute rejection occurs when the recipient’s immune system recognizes the transplanted kidney as foreign and mounts an immune response against it. This immune response can lead to damage and dysfunction of the transplanted organ. In this case, the increase in serum creatinine levels (from 140 μmol/L to 190 μmol/L) suggests a deterioration in kidney function. The normal range for serum creatinine is given as 60 – 120 μmol/L, and the rise in creatinine levels outside this range indicates impaired kidney function. Other potential causes of post-transplant kidney dysfunction should also be considered, such as: 1. Acute Tubular Necrosis (ATN): Ischemic injury to the transplanted kidney during the transplant process or other factors may lead to acute tubular necrosis, causing a temporary decrease in kidney function. 2. Drug-Induced Nephrotoxicity: Certain medications, including immunosuppressive drugs used to prevent rejection (such as calcineurin inhibitors like tacrolimus or cyclosporine), can cause nephrotoxicity and affect kidney function. 3. Infection: Post-transplant infections, particularly urinary tract infections or systemic infections, can impact kidney function. 4. Vascular Complications: Issues such as thrombosis or stenosis of the blood vessels supplying the transplanted kidney can lead to reduced blood flow and impaired function. To determine the specific cause of the decline in kidney function, additional diagnostic tests, such as kidney biopsy, ultrasound, and blood tests, may be necessary. Monitoring for signs of rejection and infections, as well as adjusting immunosuppressive medications, are important aspects of managing post-transplant kidney dysfunction. Types of transplant rejection: 1) Hyperacute rejection: – Rare. Occurs very early and is untreatable. – Due to preformed antibodies. On table black kidney. – Predictable by cytotoxic cross match 2) Acute rejection (up to 25%): – Occurs early but treatable. – T cell mediated vs Antibody mediated – Diagnosis by biopsy Pathology: – T cell mediated: – Cellular/ interstitial- tubulitis, infiltrate.Vascular/glomerular- endothelialitis – Antibody mediated: PMNs, deposition of complement component C4d+ Differential diagnoses: – Volume depletion – ATN – Interstitial nephritis – Drugs: Calcineurin toxicity, Bactrim. – Obstruction – HUS – Infection with CMV, BK virus (beyond 4 weeks) 3) Chronic rejection (30%): – Occurs late. no specific treatment. – Unknown etiology. – Progressive renal dysfunction, proteinuria, hypertension. – Diagnosed clinically from biopsy – DDX: GN, drugs, HT. Management of acute rejection: 1) Obtain tissue diagnosis. 2) IV methylprednisone 500-1000 mg daily for 3 days. 3) Failure to respond is an indication for antibody therapy, usually with OKT3 or antithymocyte depleting antibodies. 4) +/- increase in Calcineurin inhibitor (only if levels subtherapeutic) 5) Plasma exchange, IVIG or Rituximab for antibody mediated rejection. 6) Rescue: Refractory or recurrent rejection- use high dose Tacrolimus or MMF. Practice Points: Clinical evidence of rejection is rarely characterized by fever, swelling, and tenderness over the allograft. Rejection may present only with a rise in serum creatinine, with or without a reduction in urine volume. Diagnostic ultrasound is the procedure of choice to rule out urinary obstruction or to confirm the presence of perirenal collections of urine, blood, or lymph. Diagnosis of rejection is by renal biopsy. Calcineurin inhibitors have an afferent arteriolar constrictor effect on the kidney and may produce permanent vascular and interstitial injury after sustained high-dose therapy. Features to suggest calcineurin inhibitor toxicity include interstitial fibrosis, isometric tubular vacuolization, and thickening of arteriolar walls. Basically, if the biopsy does not reveal moderate and active cellular rejection activity, the serum creatinine will most likely respond to a reduction in dose.

Answer 82

The correct answer is rise in serum creatinine. When renal function has been good initially, a rise in the serum creatinine level is the most sensitive and reliable indicator of possible rejection and may be the only sign. The leading causes of transplant failure, excluding death, are alloimmune injury and recurrent glomerulonephritis. The Australian data registry reports rates of annual graft loss and death with functioning grafts of 2.6 and 2.2 events per 100 graft-years, respectively, and a combined rate of 4.7 events per 100 graft-years. During the first year after transplantation, most graft losses were due to technical issues and vascular complications (41% of graft losses), followed by acute rejection (17%) and glomerulonephritis (3%). Beyond 1 year, most graft losses were due to chronic rejection (63%) and glomerulonephritis (6%). The primary causes of death with a functioning graft during the first year after transplantation were cardiovascular disease (31% of deaths), infection (31%), and cancer (7%). After the first year, the primary causes of death were cancer (29%), cardiovascular disease (23%), and infection (12%).

Answer 83

The correct answer is increased distal tubular potassium secretion. The most likely mechanism for hypokalemia in a patient who develops metabolic alkalosis secondary to prolonged vomiting is increased distal tubular potassium secretion. Prolonged vomiting leads to loss of gastric acid (HCl), which results in metabolic alkalosis (increased blood pH). In response to metabolic alkalosis, the kidneys try to compensate by increasing bicarbonate (HCO3-) excretion and enhancing H+ secretion in the distal tubules. To maintain electroneutrality, the increased H+ secretion is accompanied by increased K+ secretion in the distal tubules, leading to increased urinary potassium loss and hypokalemia. The other options are less likely: – Increased intracellular exchange of potassium for hydrogen occurs in acidosis, not alkalosis. – Increased urinary loss of ketones is not directly related to hypokalemia in this case. – Increased pancreatic potassium secretion is not a significant factor in this scenario. – While vomiting can lead to some gastric loss of potassium chloride, the main mechanism for hypokalemia is the renal compensation for metabolic alkalosis. Therefore, increased distal tubular potassium secretion is the most likely mechanism for hypokalemia in a patient with metabolic alkalosis secondary to prolonged vomiting

Answer 84

The correct answer is Abdominal fat pad biopsy. The working diagnosis for this case is AL (light-chain) amyloidosis, and therefore, the most appropriate next step is to perform an abdominal fat pad biopsy. Diagnosis of AL amyloidosis is established by the presence of a serum or urine monoclonal protein and amyloid deposition seen on a tissue biopsy specimen. Among the many types of amyloidosis, nearly all cases of clinical cardiac amyloidosis (>95 percent) are caused by transthyretin amyloidosis (ATTR) or light chain amyloidosis (AL) Affected tissues stained with Congo red should reveal characteristic apple-green birefringence under polarized microscopy. Type of amyloidosis: 1) AL (light chain) or primary systemic amyloidosis- most common. Heavy chain is rare and is associated with multiple myeloma, plasma cell disorder and lymphoma. 2) Wild Type (none-hereditary) ATTR amyloidosis. 3) Hereditary ATTR Amyloidosis (autosomal-dominant disorder caused by deformities of transthyretin) Other rare types: serum Amyloid A (AA) Amyloidosis and Apolipoprotein-A-1 amyloidosis. Clues to diagnosis of AL Amyloidosis: – fatigue, weight loss, enlarged tongue, and easy bruising, hepatomegaly – Presence of urine monoclonal protein. – Kidney involvement -nephrotic syndrome with large amounts of non-light-chain proteinuria, and azotemia develops late in the disease course. – Cardiac involvement- thickening of the septum resulting in heart failure and arrhythmias (Digoxin is contraindicated) – Peripheral nerve involvement-sensorimotor neuropathy. – A bleeding diathesis also may be present. Clues to diagnosis of AA Amyloidosis: – History of chronic inflammatory disorders and chronic infection – Often presents with chronic kidney disease, with hepatomegaly and splenomegaly. – Macroglossia is not a feature and cardiac involvement is rare. Detection of monoclonal immunoglobulin in serum, blood, or tissues differentiates AL amyloidosis from other forms of amyloidosis. The presence of a serum or urine monoclonal protein and amyloid deposition seen on a tissue biopsy specimen is diagnostic of AL amyloidosis. Treatment of AL Amyloidosis: Assess eligibility for autologous hematopoetic cell transplantation (HCT). Induction therapy with Daratumumab in addition to bortezomib, cyclophosphamide, and dexamethasone (dara-CyBorD) followed by High dose melphalan and autologous HCT. dara-CyBordD or BMD (bortezomib, melphalan, dexamethasone) if not a candidate for HCT. Treatment of wild type ATTR amyloidosis: Tafamidis – reduces all-cause mortality and cardiovascular-related hospitalizations and reduces decline in functional capacity and quality of life as compared with placebo. Liver transplantation is not indicated as the precursor protein is native TTR. Treatment of AA Amyloidosis: TNF alpha blocker, improves the renal function in AA-type renal amyloidosis, as well as suppresses the inflammatory reactions in patients with rheumatoid arthritis. Treament of Hereditary ATTR Amyloidosis: Liver transplant is definitive therapy. LATEST: Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis NEJM October 2023.

Answer 85

The correct answer is CT angiography. The patient’s presentation with severe hypertension, abdominal bruit, and laboratory findings suggests the possibility of renal artery stenosis (RAS), particularly fibromuscular dysplasia (FMD). The abdominal bruit is a key clinical clue. The findings that support this diagnosis: 1. Difficult-to-treat Hypertension: Hypertension that is challenging to manage, especially in a young individual with no family history of hypertension, raises suspicion for secondary causes. 2. Prominent Precordial Heave: This may be an indicator of increased cardiac output, which can be seen in conditions associated with renal artery stenosis. 3. Abdominal Bruit: The presence of an abdominal bruit suggests a vascular abnormality, such as renal artery stenosis. Fibromuscular dysplasia (FMD) is a non-atherosclerotic and non-inflammatory arterial disease that commonly affects the renal arteries and can lead to stenosis. 4. Grade 2 Hypertensive Retinopathy: Hypertensive retinopathy is a manifestation of long-standing and severe hypertension. 5. Normal Plasma Renin Activity: The plasma renin activity is inappropriately normal in the context of hypertension. In renovascular hypertension, the affected kidney perceives reduced perfusion and responds by increasing renin secretion. However, in this case, the plasma renin activity is not elevated, which is unusual for primary renovascular hypertension. In terms of diagnostic imaging, CTA is preferred over contrast-enhanced magnetic resonance angiography (MRA) due to its superior spatial resolution and ability to visualize small calcifications, which helps differentiate FMD from atherosclerotic renal artery stenosis. While duplex ultrasound can be used in specialized centers, it is not recommended as the initial test for FMD. If CTA or MRA confirms FMD or if there remains a high suspicion despite negative results, catheter-based angiography may be performed, as it is the gold standard for assessing the location and morphology of FMD. However, this is only indicated when it will influence patient management. Additional assessments like measuring translesional pressure gradients may also be necessary to evaluate the hemodynamic significance of stenosis, especially in multifocal FMD Some Take Home messages about FMD: Clues to diagnosis: young age less than 40 severe hypertension with evidence of target organ damage. mild hypokalemic metabolic alkalosis and high renin suggest underlying renovascular hypertension. abdominal bruit Fibromuscular dysplasia: Women(almost 100%) age 15-40 total occlusion is rare ischaemic atrophy is rare surgical intervention or PTRA has good cure rates. Angio findings show narrowing at distal two-thirds of the main renal artery. “String of beads” apppearance. Diagnosis: CT angiography as first line, if unavailable, then MRA. Gold standard is with intra-arterial angiography but only necessary if it changes management.

Answer 86

The correct answer is chronic allograft nephropathy. Loss of renal function five years after renal transplantation can be attributed to various factors. One of the common causes is chronic allograft nephropathy, also known as chronic rejection. Chronic rejection is a gradual process where the transplanted kidney undergoes progressive damage over time. Some key factors that may contribute to the loss of renal function five years after renal transplantation: 1. Chronic Allograft Nephropathy (Chronic Rejection): Chronic rejection is a common cause of late graft loss. It involves immune-mediated damage to the renal allograft, leading to fibrosis and scarring of the kidney tissue over time. Chronic allograft nephropathy may not present with obvious symptoms early on, and the decline in kidney function may be gradual. 2. Immunosuppression-related Issues: Long-term use of immunosuppressive medications, while crucial for preventing acute rejection, can have side effects and may contribute to chronic kidney damage over time. Adjustments to the immunosuppressive regimen may be necessary to balance the need for immune suppression with the risk of medication-related complications. 3. Recurrence of Primary Disease: In some cases, the original disease that led to the need for a kidney transplant can recur in the transplanted kidney, contributing to chronic kidney damage. 4. Vascular Issues: Problems with the blood vessels supplying or draining the transplanted kidney, such as renal artery stenosis or thrombosis, can lead to ischemic damage and contribute to the loss of renal function. 5. Infections: Persistent or recurrent infections in the transplanted kidney can also contribute to chronic kidney damage. 6. Chronic Medication-related Toxicity: Some medications used in the post-transplant period, such as calcineurin inhibitors, may have long-term toxic effects on the kidneys and contribute to chronic nephropathy. Regular monitoring of kidney function, including serum creatinine levels and periodic kidney biopsies, is essential in the post-transplant period to detect any signs of graft dysfunction early. Management strategies will depend on the specific cause of the decline in renal function and may involve adjustments to immunosuppressive medications, treatment of infections, and addressing other contributing factors. It’s crucial for patients to work closely with their transplant team to optimize care and address issues promptly. Chronic rejection can be divided into immunologic and non-immunologic: Immunologic: – cell mediated – antibody mediated Non-immunologic: – Response to injury – Calcineurin toxicity – Recurrent disease – Hyperfiltration – Hypertension – Lipids

Answer 87

The correct answer is Chronic interstitial fibrosis Chronic allograft nephropathy (CAN), also known as chronic rejection, is a common cause of late graft dysfunction and loss following kidney transplantation. One of the most common histologic features seen in chronic allograft nephropathy, particularly after 5 years of transplantation, is interstitial fibrosis and tubular atrophy (IF/TA). Interstitial fibrosis and tubular atrophy are characteristic histological findings in the chronically damaged renal allograft. These changes represent the scarring and loss of functional kidney tissue over time. The fibrosis involves the interstitium (the tissue between the renal tubules), and atrophy involves the loss of functional renal tubules. Other histologic features that may be observed in chronic allograft nephropathy include: 1. Arterial Fibrointimal Thickening: Chronic rejection can lead to thickening of the walls of arteries within the transplanted kidney, known as fibrointimal thickening. 2. Glomerulosclerosis: Although not as prominent as in some other kidney diseases, chronic allograft nephropathy may also involve sclerosis (scarring) of the glomeruli. 3. Vascular Changes: Changes in the blood vessels, including narrowing or occlusion, may contribute to ischemic damage in the graft. 4. Lymphocytic Infiltration: While acute rejection is characterized by significant lymphocytic infiltration, chronic allograft nephropathy may still show some degree of chronic inflammation. The progression of chronic allograft nephropathy is often insidious, and these histologic changes may be associated with a gradual decline in renal function over time. Early detection through regular monitoring of kidney function and, if needed, kidney biopsy, allows for timely intervention and management. Management strategies for chronic allograft nephropathy often involve optimizing immunosuppressive medications, addressing modifiable risk factors, and managing complications to slow the progression of kidney damage. In some cases, if graft function continues to decline despite interventions, reevaluation for potential retransplantation may be considered.

Answer 88

The correct answer is Nephropathy Following kidney transplantation, the most likely manifestation of BK virus infection is BK virus-associated nephropathy (BKVAN). BK virus is a polyomavirus that can cause infections in immunocompromised individuals, such as transplant recipients. BK Virus-Associated Nephropathy (BKVAN) typically occurs in the first year or two after transplantation, but it can occur later. The hallmark of BKVAN is renal dysfunction, manifested by an increase in serum creatinine levels. This decline in kidney function may be gradual. Histologically, BKVAN is characterized by the presence of intranuclear inclusions (decoy cells) in the renal tubular epithelial cells. These inclusions are indicative of viral replication. In addition to the presence of viral inclusions, there is often interstitial inflammation and fibrosis in the affected areas of the kidney. While BKVAN primarily affects the kidneys, BK virus can also cause hemorrhagic cystitis, especially in the early post-transplant period. Hemorrhagic cystitis involves inflammation and bleeding in the bladder. Regular monitoring of serum creatinine levels and urine for the presence of BK virus DNA are crucial in detecting BKVAN. The primary approach to managing BKVAN involves reducing immunosuppressive medications to allow the immune system to control the viral replication. However, this needs to be carefully balanced to prevent rejection of the transplanted organ. Antiviral medications, such as cidofovir or leflunomide, have been used in some cases, although their efficacy is not well-established, and they may have potential toxicities. Preventing and managing BKVAN is an important aspect of post-transplant care. Close monitoring of kidney function and regular surveillance for BK virus replication are key components of the management strategy. The specific approach may vary based on individual patient factors, the severity of the infection, and the overall balance between preventing rejection and controlling viral replication. Some quick pointers on BK Nephropathy: – Caused by BK virus (polyomavirus) – affects renal transplanted kidneys > native kidneys. – results in deterioration of graft function if not detected early. How to detect BK virus? – BK virus DNA detection in plasma (PCR) is found in 100% of patients with BK nephropathy. – Decoy cells in urine characteristic but not pathognomonic. What does biopsy show? – Biopsy shows interstitial nephritis and tubular injury. – Intranuclear viral inclusions seen exclusively in epithelial cells – Distal tubule and Collecting ducts most involved. When does it occur? – Between 2 to 60 months ( median 9 months) post transplant. – May present with progressive graft dysfunction with NO SYMPTOMS. – Graft failure in 45% of affected patients. Who it at risk? – On immunosuppressants- Tacrolimus and MMF – Recurrent episodes of rejection – HLA mismatch – Men How to treat? – Reduce immunosuppression – No specific antiviral available as yet.

Answer 89

The correct answer is OKT3 OKT3 (muromonab-CD3) is a monoclonal antibody that targets the CD3 receptor on the surface of T lymphocytes. It was historically used as an immunosuppressive therapy, particularly in the context of organ transplantation to prevent acute rejection. The mechanism of action of OKT3 involves its interaction with T cells and modulation of the immune response. Here’s a breakdown of the mechanism: 1. Targeting CD3 Receptor: CD3 is a complex of proteins associated with the T-cell receptor (TCR) on the surface of T lymphocytes. OKT3 specifically binds to the CD3 epsilon chain on T cells. 2. Inhibition of T-Cell Activation: The engagement of OKT3 with CD3 on the T-cell surface interferes with the normal activation of T cells in response to antigens. This inhibits the signaling cascade initiated by the T-cell receptor, preventing the activation and proliferation of T cells. 3. T-Cell Depletion: OKT3 treatment can also lead to the depletion of T cells by promoting their binding to Fc receptors on macrophages. This triggers antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in the destruction of T cells. 4. Suppression of Immune Response: By inhibiting T-cell activation and promoting T-cell depletion, OKT3 effectively suppresses the cellular immune response. This is particularly relevant in the context of organ transplantation, where the goal is to prevent the recipient’s immune system from attacking and rejecting the transplanted organ. It’s important to note that while OKT3 was historically used as an effective immunosuppressive therapy, its use has declined over the years due to the availability of newer and more targeted immunosuppressive agents with potentially fewer side effects. Additionally, OKT3 is associated with certain side effects, such as cytokine release syndrome, which can lead to flu-like symptoms, fever, and other reactions. Modern immunosuppressive regimens often rely on calcineurin inhibitors, antimetabolites, and monoclonal antibodies targeting specific pathways involved in the immune response.

Answer 90

The correct answer is Prednisone monotherapy. Among the commonly used immunosuppressive agents, corticosteroids are least likely to be effective as a sole treatment for acute renal allograft rejection. Corticosteroids, such as prednisone, are often used in combination with other immunosuppressive medications to prevent and treat acute rejection, but they are generally not considered the primary agent for treating established acute rejection. The standard treatment for acute renal allograft rejection typically involves the use of more potent immunosuppressive medications such as: 1. Antithymocyte Globulin (ATG): Polyclonal antibodies derived from rabbits or horses, such as antithymocyte globulin, are commonly used to treat acute rejection. They work by depleting T lymphocytes, suppressing the immune response. 2. Monoclonal Antibodies: Specific monoclonal antibodies, such as basiliximab or alemtuzumab, may be used to target specific pathways involved in the immune response. 3. Calcineurin Inhibitors: Medications like tacrolimus or cyclosporine, which inhibit calcineurin and block T-cell activation, are fundamental in preventing and treating acute rejection. 4. Mycophenolate Mofetil (MMF): An antimetabolite that inhibits the proliferation of T and B lymphocytes. Corticosteroids are often used as part of the initial treatment regimen for acute rejection, but they are typically combined with other more targeted immunosuppressive agents to enhance efficacy and reduce the risk of rejection recurrence. The choice of treatment depends on the severity of rejection, the immunologic risk of the patient, and the specific protocols followed by the transplant center. Principles of Management of acute rejection: 1) Obtain tissue diagnosis. 2) IV methylprednisone 500-1000 mg daily for 3 days. 3) Failure to respond is an indication for antibody therapy, usually with an antithymocyte depleting antibodies. 4) +/- increase in Calcineurin inhibitor (only if levels subtherapeutic) 5) Plasma exchange, IVIG or Rituximab for antibody mediated rejection. 6) Rescue: Refractory or recurrent rejection- use high dose Tacrolimus or MMF.

Answer 91

The correct answer is mycophenolate toxicity. Mycophenolate is not known to cause nephrotoxicity. The primary active form of mycophenolate mofetil is mycophenolic acid (MPA). Some aspects of mycophenolate toxicity include: 1. Gastrointestinal Toxicity: Nausea and Vomiting: Gastrointestinal symptoms, including nausea and vomiting, are common side effects of mycophenolate. Taking the medication with food may help alleviate these symptoms. Diarrhea is also a frequent adverse effect. In some cases, diarrhea may be severe and persistent, leading to dose adjustments or discontinuation of the drug. 2. Hematologic Toxicity: Bone Marrow Suppression: Mycophenolate can suppress the bone marrow, leading to decreased production of blood cells. This may result in anemia, leukopenia (low white blood cell count), and thrombocytopenia (low platelet count). 3. Infections: Increased Susceptibility: Mycophenolate, by suppressing the immune system, can increase the risk of infections. This includes viral, bacterial, and fungal infections. Patients on mycophenolate are often closely monitored for signs of infection. 4. Hepatotoxicity: Elevated Liver Enzymes: Mycophenolate can cause an increase in liver enzyme levels. Regular monitoring of liver function is typically performed, and dose adjustments may be made if significant hepatotoxicity occurs. 5. Pulmonary Toxicity: Interstitial Lung Disease: Rare cases of interstitial lung disease have been reported in patients receiving mycophenolate. Symptoms may include cough, shortness of breath, and fever. 6. Immunosuppression-Related Malignancies: Increased Risk: Long-term immunosuppression, including mycophenolate use, is associated with an increased risk of certain malignancies, such as lymphomas and skin cancers. 7.GI Ulceration (Rare): Gastrointestinal Ulcers: Rarely, mycophenolate has been associated with gastrointestinal ulceration. Patients experiencing severe abdominal pain or gastrointestinal bleeding should seek medical attention promptly.

Answer 92

The correct answer is CMV disease CMV disease: In severe cases, CMV infection can cause organ-specific manifestations, affecting various organs, including the lungs, liver, gastrointestinal tract, and central nervous system. CMV pneumonia is a potentially severe complication that can lead to respiratory failure. CMV can also cause colitis, gastritis, or hepatitis, leading to symptoms such as abdominal pain, diarrhea, and liver dysfunction. Who is at risk? – exposure increases with age. – on immunosuppresions – on anti-T cell induction therapy. – reactivation common with OKT3. CMV infection vs CMV disease – CMV Infection is detection of CMV in blood. – CMV disease is when patient presents with clinical signs and symptoms. How to prevent? – CMV prophylaxis with oral Valganciclovir for everyone undergoing renal transplant except if both donor and recipient are CMV negative. Prevention and Management: Antiviral Prophylaxis: Many renal transplant recipients receive antiviral prophylaxis with medications like valganciclovir or ganciclovir to prevent CMV infection. Preemptive Therapy: In some cases, a strategy called preemptive therapy is used, where antiviral treatment is initiated based on regular monitoring of CMV viral load. Monitoring: Regular monitoring for CMV through blood tests, such as CMV PCR, is essential to detect and manage infections promptly.

Answer 93

The correct answer is mycophenolate. Mycophenolate mofetil, an antimetabolite, is commonly used in renal transplantation. However, it is not strongly associated with hyperglycemia compared to corticosteroids or calcineurin inhibitors. Several medications commonly used in the context of renal transplantation can contribute to hyperglycemia or diabetes. This is particularly relevant because renal transplant recipients are at an increased risk of developing new-onset diabetes after transplantation (NODAT). Here are some medications associated with an increased risk of hyperglycemia: 1. Corticosteroids (Prednisone): – Corticosteroids are commonly used as part of immunosuppressive regimens in renal transplantation. – They can induce insulin resistance, leading to elevated blood glucose levels. 2. Calcineurin Inhibitors: – Tacrolimus: Tacrolimus is a calcineurin inhibitor frequently used in renal transplantation. – Tacrolimus has been associated with new-onset diabetes after transplantation (NODAT). – Cyclosporine: Another calcineurin inhibitor, cyclosporine, is also linked to an increased risk of diabetes. 3. Sirolimus (mTOR Inhibitors): – Sirolimus, an mammalian target of rapamycin (mTOR) inhibitor, is used in some immunosuppressive regimens. – It has been associated with insulin resistance and an increased risk of hyperglycemia. 4. Mycophenolate Mofetil (MMF): – Mycophenolate mofetil, an antimetabolite, is commonly used in renal transplantation. – While it is not as strongly associated with hyperglycemia as corticosteroids or calcineurin inhibitors, some studies suggest a potential link. 5. Antithymocyte Globulin (ATG): – ATG, a polyclonal antibody used for induction immunosuppression, may contribute to the development of diabetes in some cases. 6. Antibiotics (Trimethoprim-Sulfamethoxazole): – Trimethoprim-sulfamethoxazole, commonly used for infection prophylaxis, can increase blood glucose levels.

Answer 94

✅ Correct answer 👉 Kaposi’s sarcoma 🧠 Why this is the right one Sirolimus (rapamycin) is an mTOR inhibitor. mTOR = cell growth, proliferation, angiogenesis. Kaposi’s sarcoma: Driven by HHV-8 Highly angiogenesis-dependent Thrives under calcineurin inhibitors 👉 Switching from a calcineurin inhibitor to sirolimus can: Slow progression Cause regression of Kaposi’s sarcoma Reduce tumour vascularity This isn’t just theoretical — it’s clinically observed. 🚫 Why not the others? ❌ Non-Hodgkin’s lymphoma (PTLD) Related to EBV + immunosuppression Risk reduced mainly by lowering immunosuppression Sirolimus is not specifically protective ❌ Squamous cell carcinoma of the skin Very common post-transplant Sirolimus may reduce incidence over time BUT does not reverse or slow established disease Exam wants a clearer association ❌ Chronic myeloid leukaemia BCR-ABL driven No role for mTOR inhibition here ❌ Carcinoma of the prostate No meaningful protective effect from sirolimus 🧩 Exam takeaway (gold-star level) Kaposi’s sarcoma is the one transplant malignancy that may improve when switching to sirolimus If you see: Kaposi’s mTOR inhibitor transplant patient 👉 Click. It. Immediately.

Answer 95

The correct answer is Azathioprine. When immunosuppression is necessary (eg, in renal transplant recipients, recently active lupus, or IBD), AZA or 6-MP can be used during pregnancy. While these medications do not appear to increase the risk of teratogenicity, higher rates of other pregnancy complications (low birth weight, prematurity, and jaundice) have been reported. AZA is also considered compatible with breastfeeding. Available evidence suggests that excretion of AZA in breast milk is very low in most women. The rest of the above are teratogenic and therefore should be avoided during pregnancy.

Answer 96

The correct answer is diabetes For men, the relative risks for diabetes mellitus were 2.78 (1.73 to 4.49) and 1.53 for the transplant recipient and Framingham Heart Study (FHS) populations, respectively; the relative risks for age (in years) were 1.06 (1.04 to 1.08) and 1.05, respectively, and those for smoking were 1.95 (1.20 to 3.19) and 1.69, respectively. For women, the relative risks for diabetes mellitus were 5.40 (2.73 to 10.66) and 1.82, respectively.

Answer 97

The correct answer is Cystatin C detects renal dysfunction earlier than creatinine. Cystatin C levels rise earlier than creatinine levels when there is a decline in glomerular filtration rate (GFR), allowing for the detection of kidney dysfunction in its early stages, including acute kidney injury (AKI). This is especially important in the “creatinine blind area,” where mild declines in GFR may not yet manifest as elevated creatinine levels. In addition, serum creatinine levels are generally influenced by muscle mass, age, gender, race, and dietary protein intake. But in contrast, cystatin C levels are not significantly affected by these factors, making it a more reliable indicator of kidney function across diverse populations, including extremes of muscle mass such as bodybuilders, the elderly, and those with muscle-wasting diseases.

Answer 98

The correct answer is Increased renin secretion leading to vasoconstriction of afferent arterioles. Under conditions of low blood volume or low renal perfusion pressure, JG cells detect these changes and secrete renin. Renin converts angiotensinogen, produced by the liver, into angiotensin I, which is then converted to angiotensin II primarily in the lungs. Angiotensin II acts as a potent vasoconstrictor that primarily affects the efferent arterioles but can lead to a net increase in overall vascular resistance, affecting the afferent arterioles as well. This response conserves fluid and helps maintain blood pressure.

Answer 99

The correct answer is Dialysis disequilibrium syndrome The clinical scenario describes a patient with end-stage renal disease (ESRD) who is undergoing his first session of hemodialysis and develops symptoms including headache, nausea, confusion, and visual disturbances. These symptoms present during the dialysis session and are associated with a significant decrease in blood urea nitrogen (BUN) levels. Dialysis Disequilibrium Syndrome or DDS is a condition that occurs during or after hemodialysis, especially in patients who are new to the treatment. It is characterized by neurological symptoms that result from the rapid removal of urea and other toxins from the blood, leading to osmotic imbalances between the brain and the plasma. This osmotic shift can cause cerebral edema and increased intracranial pressure. Key Points Supporting DDS: Timing: The symptoms develop during the first hour of hemodialysis, a common time frame for DDS onset. Symptoms: Headache, nausea, confusion, and visual disturbances are classic presenting symptoms of DDS. Significant BUN Decrease: A rapid reduction in BUN levels is a hallmark of DDS as it leads to the osmotic shift and subsequent cerebral edema. Absence of Infection Signs: The patient has no signs of infection, making sepsis less likely. Therefore, given the clinical presentation, the timing related to the dialysis session, and the significant decrease in BUN levels, the most likely diagnosis is Dialysis Disequilibrium Syndrome (DDS).

Answer 100

The correct answer is Lactate. The most common buffer in peritoneal dialysis (PD) fluid is Lactate. Peritoneal dialysis (PD) fluid typically contains lactate as the primary buffer. Lactate is included in the PD solution to help neutralize the acidic environment created by the accumulation of uremic toxins in patients with renal failure. During the process of dialysis, lactate is metabolized in the liver to bicarbonate, which then acts to buffer the blood and maintain acid-base balance. Sodium, calcium, chloride, and magnesium are also present in PD fluids but serve different roles, such as maintaining electrolyte balance and osmolarity. CHAT GPT ✅ Correct answer 👉 Lactate 🧠 Why lactate? In peritoneal dialysis (PD) fluid: The buffer is lactate (most commonly ~35–40 mmol/L) Lactate is: Stable in solution Metabolised by the liver → bicarbonate Easy to store and cheap 👉 So lactate = quiet hero doing acid–base housekeeping. 🚫 Why not the others? Sodium → main cation, not a buffer Chloride → counter-ion, not buffering pH Calcium / Magnesium → electrolytes only (👀 Bicarbonate can be used in some newer solutions, but lactate is still the most common — exam answer locked.) 🧩 One-liner to remember PD buffers acid with lactate → liver turns it into bicarbonate

Answer 101

The correct answer is Her weekly Kt/V and creatinine clearance are both adequate, indicating optimal dialysis. To ensure that dialysis is effectively removing waste products from the blood, the clinician needs to measure the dialysis adequacy. Two primary metrics used to evaluate this are Weekly Kt/V and Weekly creatinine clearance. Weekly Kt/V Concept: Kt/V is a dimensionless number that quantifies the efficacy of dialysis by comparing the amount of urea removed to the total body water. K stands for the dialyzer clearance of urea (rate at which urea is removed). t represents the time over which dialysis occurs. V is the volume of distribution of urea, which approximates the patient’s total body water. Calculation: For peritoneal dialysis (PD), Kt/V is typically calculated on a weekly basis. The formula for weekly Kt/V in PD can be simplified as: Weekly Kt/V = Total urea removed per week/Total body water Target Values: The recommended target for adequate peritoneal dialysis is a weekly Kt/V of at least 1.7. Significance: A higher Kt/V indicates more effective removal of urea, suggesting better dialysis adequacy. Monitoring Kt/V helps in adjusting dialysis prescriptions to ensure patients receive adequate treatment. Weekly Creatinine Clearance Concept: Creatinine clearance measures the efficiency with which the kidneys (or dialysis) can remove creatinine from the blood. It provides an estimate of the rate at which waste is cleared and is usually expressed in liters per week for PD. Calculation: Creatinine clearance is calculated by measuring the amount of creatinine in the dialysate and urine (if the patient still has some residual kidney function) and comparing it to the plasma creatinine concentration. The formula for weekly creatinine clearance in PD is: Creatinine Clearance (L/week) = Total creatinine removed per week / Plasma creatinine concentration. Target Values: The generally accepted target for weekly creatinine clearance in PD is at least 60 L/week/1.73m². Significance: Creatinine clearance provides additional information about the removal of middle molecules and other toxins not captured by Kt/V alone. It is particularly useful for patients with significant residual renal function, as it accounts for both dialysis and kidney clearance. Combined Use Importance: Using both Kt/V and creatinine clearance provides a comprehensive assessment of dialysis adequacy. This dual approach ensures that both small solute (urea) and middle molecule (creatinine) clearances are optimized, leading to better patient outcomes. Clinical Application: Regular monitoring of these metrics allows for timely adjustments in dialysis prescription, such as changing the dialysis fluid, adjusting dwell times, or modifying the frequency of exchanges. Ensuring adequate dialysis prevents complications associated with under-dialysis, such as fluid overload, electrolyte imbalances, and accumulation of toxins, which can lead to poor quality of life and adverse health outcomes. So based on the above concepts, we can now perform the following calculations: Weekly Kt/V Calculation: Weekly Kt/V = Total urea removed per week/Total body water Weekly Kt/V = 150,000 mg/ 35,000 mL = 150/35 Weekly Kt/V = 4.29 Target: The recommended target for adequate peritoneal dialysis is a weekly Kt/V of at least 1.7. Interpretation: A weekly Kt/V of 4.29 is well above the target, indicating good urea clearance. Weekly Creatinine Clearance Calculation: Weekly Creatinine Clearance (L/week) = Total creatinine removed per week/Plasma creatinine concentration Weekly Creatinine Clearance = 6000 mg/ 8 mg/dL Weekly Creatinine Clearance = 750 dL/week Weekly Creatinine Clearance} = 75 L/week Target: The generally accepted target for weekly creatinine clearance in PD is at least 60 L/week/1.73m². Interpretation: A weekly creatinine clearance of 75 L/week is above the target, indicating good creatinine clearance. Given these calculations, both the weekly Kt/V and weekly creatinine clearance are adequate, indicating optimal dialysis.

Answer 102

The correct answer is Reduction of glomerular hyperfiltration In patients with IgA nephropathy, glomerular hyperfiltration is a common pathophysiological feature. Glomerular hyperfiltration refers to an increase in the rate at which blood is filtered by the glomeruli in the kidneys. This increased filtration can lead to damage to the glomerular filtration barrier and exacerbate kidney injury over time. SGLT-2 inhibitors, which are commonly used in the treatment of diabetes, exert their effects by inhibiting the sodium-glucose cotransporter 2 in the proximal tubules of the kidneys. By blocking this transporter, SGLT-2 inhibitors reduce the reabsorption of glucose and sodium in the proximal tubules, leading to glycosuria and natriuresis. The reduction in sodium reabsorption results in a mild osmotic diuresis and natriuresis, leading to a decrease in plasma volume and systemic blood pressure. This natriuretic effect also contributes to a reduction in glomerular hyperfiltration, thereby alleviating the hemodynamic stress on the glomeruli. Furthermore, SGLT-2 inhibitors have been shown to decrease intraglomerular pressure and reduce kidney injury by modulating the tubuloglomerular feedback mechanism. This mechanism involves the interaction between the macula densa cells in the distal tubule and the afferent arteriole of the glomerulus, regulating the glomerular filtration rate. By reducing glomerular hyperfiltration and intraglomerular pressure, SGLT-2 inhibitors help to preserve renal function and reduce proteinuria in patients with IgA nephropathy. Additionally, the hemodynamic and metabolic effects of SGLT-2 inhibitors may also contribute to their renoprotective effects in these patients. So in conclusion, the reduction of glomerular hyperfiltration through the modulation of tubular sodium reabsorption is the key mechanism by which SGLT-2 inhibitors improve renal outcomes in patients with IgA nephropathy. This targeted approach addresses the underlying pathophysiology of kidney injury in these patients and highlights the potential benefits of SGLT-2 inhibitors in the management of IgA nephropathy. Previous Lesson Back to Course

Answer 103

The correct answer is Administration of steroid therapy for 6 months In the management of IgA nephropathy, standard treatment options for patients with mild proteinuria, such as less than 1g/day, typically include measures to control blood pressure, optimize renal function, and reduce the risk of disease progression. Recent clinical trials such as the TESTING trial published in JAMA in 2022 have provided valuable insights into the optimal treatment approaches for patients with this condition. The TESTING trial, a randomized controlled trial, evaluated the efficacy and safety of steroid therapy in patients with IgA nephropathy and moderate proteinuria. The findings of the trial highlighted the importance of individualized treatment decisions in IgA nephropathy based on the patient’s risk profile and disease severity. The trial demonstrated that while steroid therapy may be beneficial in certain patient subgroups with IgA nephropathy, it may not be suitable for all patients, especially those with milder forms of the disease. For a 45-year-old patient with mild proteinuria of less than 1g/day, the results of the trial suggest that the decision to initiate steroid therapy should be carefully considered and based on factors such as the level of proteinuria, renal function, histological findings, and the presence of risk factors for disease progression. In light of this finding, standard management strategies such as the initiation of RAS blockade, tight blood pressure control, dietary sodium restriction, and lifestyle modifications remain key components of the treatment plan for patients with IgA nephropathy, particularly those with mild proteinuria. Steroid therapy, particularly the administration of corticosteroids for a prolonged period, should be reserved for patients with severe or progressive IgA nephropathy who are at risk of developing end-stage renal disease. The decision to initiate steroid therapy in IgA nephropathy is based on factors such as the severity of proteinuria, declining renal function, histological findings on kidney biopsy, and the presence of other risk factors for disease progression. Reference: Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy, JAMA May 2022. Previous Lesson Back to Course

Answer 104

The correct answer is Autoantibodies against the non-collagenous (NC1) domain of the α3 chain of Type IV collagen, leading to glomerulonephritis and alveolar hemorrhage. Anti-GBM (Goodpasture syndrome) is a rare autoimmune condition characterized by autoantibodies targeting the non-collagenous (NC1) domain of the α3 chain of Type IV collagen. This specific domain is present in the glomerular basement membrane (GBM) of the kidneys and the alveolar basement membrane in the lungs. In Anti-GBM disease, the IgG autoantibodies are directed against the NC1 domain of the α3 chain, which becomes exposed due to various triggers. These autoantibodies then bind to the NC1 domain in the GBM and alveolar basement membrane. This binding initiates an inflammatory cascade, leading to glomerulonephritis in the kidneys and alveolar hemorrhage in the lungs. Patients typically present with rapidly progressive glomerulonephritis (RPGN) and/or pulmonary hemorrhage, manifesting as hematuria, proteinuria, and hemoptysis. The diagnosis is usually confirmed by detecting anti-GBM antibodies in the serum and/or renal biopsy showing linear IgG deposits along the GBM. Treatment includes immunosuppressive therapy such as corticosteroids, cyclophosphamide and plasmapheresis to remove circulating autoantibodies.

Answer 105

✅ Correct answer 👉 Blocking the complement C5a receptor 🧠 Why this is right Avacopan is a: Selective C5a receptor (C5aR1) antagonist In ANCA-associated vasculitis: ANCA-activated neutrophils Complement pathway gets activated C5a acts as a powerful neutrophil chemoattractant and activator → neutrophil adhesion, degranulation, endothelial injury 👉 Avacopan blocks C5a from binding to its receptor, shutting down neutrophil-driven vascular damage without broad immunosuppression. This is why it can: Reduce reliance on high-dose steroids Lower steroid-related toxicity 🚫 Why not the others? ❌ Inhibition of T-cell proliferation → calcineurin inhibitors, MMF ❌ IL-6 neutralization → tocilizumab ❌ TNF-alpha inhibition → infliximab, etanercept ❌ B-cell suppression → rituximab Avacopan is complement-targeted, not adaptive immunity. 🧩 Exam pearl (lock it in) ANCA vasculitis = neutrophils + complement → block C5a If you see: Avacopan ANCA vasculitis Steroid-sparing 👉 Think C5a receptor blockade instantly.

Answer 106

The correct answer is Microscopic Polyangiitis (MPA). The patient presents with a combination of systemic symptoms (generalized weakness, weight loss, low-grade fever), pulmonary symptoms (shortness of breath, hemoptysis, bilateral crackles on auscultation), and renal involvement (elevated creatinine, hematuria, proteinuria). The serologic findings further refine the differential diagnosis. MPA is a small vessel vasculitis characterized by systemic symptoms, pulmonary involvement (often presenting as diffuse alveolar hemorrhage with hemoptysis and ground-glass opacities on imaging), and renal involvement (glomerulonephritis presenting with hematuria and proteinuria). The presence of MPO-ANCA (p-ANCA) is highly specific for MPA. Therefore, the clinical presentation and serologic findings in this patient are consistent with MPA. SLE can present with systemic symptoms and renal involvement, but it usually has a positive antinuclear antibody (ANA) and extractable nuclear antigen (ENA) profiles. So the negative ANA and ENA in this patient make SLE unlikely. GPA can present with systemic, pulmonary, and renal symptoms. However, GPA is typically associated with cytoplasmic ANCA (c-ANCA) and often has proteinase-3 (PR3-ANCA) rather than MPO-ANCA. Additionally, GPA often presents with upper respiratory tract involvement (e.g., sinusitis, nasal ulcers) and cavitating lung nodules, which are absent in this case. Goodpasture Syndrome presents with pulmonary (hemoptysis) and renal (glomerulonephritis) involvement. However, it is characterized by positive anti-glomerular basement membrane (Anti-GBM) antibodies, which are negative in this patient. PAN typically affects medium-sized arteries and does not usually involve the lungs and is typically ANCA negative. It can cause systemic symptoms and renal involvement, but the absence of lung findings and positive MPO-ANCA makes PAN unlikely. So based on the clinical presentation of systemic symptoms, pulmonary findings (hemoptysis, ground-glass opacities), renal involvement (elevated creatinine, hematuria, proteinuria), and the serologic finding of MPO-ANCA, the most likely diagnosis for this patient is Microscopic Polyangiitis (MPA). *** MPO (pANCA) = MPA - Because M and M PR3 (cANCA) = GPA - C is the 3rd letter - G comes before M

Answer 107

The correct answer is Inhibition of B-lymphocyte stimulator (BLyS) Lupus nephritis is a significant renal complication arising from systemic lupus erythematosus (SLE), an autoimmune disorder where the immune system erroneously targets the body’s own tissues, including the kidneys. This misdirected immune response leads to inflammation and progressive renal damage. In the context of lupus nephritis, B cells are of particular interest. These lymphocytes are crucial for normal immune response but become dysregulated in SLE. This dysregulation results in the production of autoantibodies, which form immune complexes that deposit in renal tissues, instigating inflammation and subsequent nephron injury. Belimumab is a novel monoclonal antibody that specifically targets and inhibits B-lymphocyte stimulator (BLyS), also known as B-cell activating factor (BAFF). BLyS is a critical cytokine for the maturation, survival, and proliferation of B cells. Elevated BLyS levels have been observed in patients with SLE, contributing to the persistence and activity of autoreactive B cells. By binding to and neutralizing BLyS, belimumab effectively reduces the survival of these autoreactive B cells. Consequently, this leads to a decrease in autoantibody production, thereby attenuating the inflammatory processes and renal damage associated with lupus nephritis. The therapeutic goal is to restore immune equilibrium by curtailing the number of pathogenic B cells and their deleterious effects.

Answer 108

✅ Correct answer 👉 C3 Glomerulopathy 🧩 Why this is the answer (step-by-step exam logic) 1️⃣ Clinical syndrome Edema + frothy urine → nephrotic-range proteinuria Microscopic hematuria present → mixed nephritic–nephrotic picture Creatinine near-normal → early disease So we’re thinking glomerular pathology, not tubules or vessels. 2️⃣ Complement pattern (this is the clincher) Low C3 Normal C4 👉 That screams alternative complement pathway activation This pattern rules OUT lupus and points directly at C3-dominant disease. 3️⃣ Biopsy finding (the knockout punch) Dense deposits within the GBM on EM That phrase is basically exam shorthand for: 💥 Dense Deposit Disease (DDD) (a subtype of C3 glomerulopathy) 🚫 Why the others are wrong ❌ Membranous nephropathy Subepithelial immune deposits (“spikes”) Complements usually normal PLA2R antibodies often present ❌ IgA nephropathy Mesangial IgA deposition Usually normal complement Often post-URTI hematuria ❌ Lupus nephritis Low C3 AND low C4 Positive ANA, anti-dsDNA “Full house” immunofluorescence ❌ Minimal Change Disease Normal light microscopy Foot process effacement on EM Normal complement No hematuria 🧠 One-liner to remember (exam gold) Low C3 + normal C4 + dense GBM deposits = C3 glomerulopathy If they say dense deposits → don’t overthink → click C3 glomerulopathy and move on like a queen 👑

Answer 109

The correct answer is Basiliximab- Binds to CD25 on activated T-cells, preventing interleukin-2 (IL-2) induced proliferation. Basiliximab: A monoclonal antibody that targets the IL-2 receptor (CD25) on activated T-cells, blocking IL-2 mediated signaling and T-cell proliferation. Tacrolimus: A calcineurin inhibitor that binds to FKBP-12, inhibiting calcineurin, which is essential for T-cell activation via the NFAT pathway. Sirolimus: Binds to FKBP-12 and inhibits the mammalian target of rapamycin (mTOR), a key regulator of T-cell proliferation. Mycophenolate: Inhibits inosine monophosphate dehydrogenase (IMPDH), crucial for the de novo synthesis of guanine nucleotides, thus inhibiting the proliferation of T- and B-cells. Anti-thymocyte globulin: A polyclonal antibody preparation that targets multiple T-cell surface antigens, leading to T-cell depletion through complement-mediated lysis and opsonization

Answer 110

The correct answer is CABMR is a major cause of long-term graft dysfunction and loss. CABMR plays a significant role in causing long-term graft dysfunction and eventual loss in organ transplant recipients. This rejection process is mediated by the continuous presence of antibodies that target the transplanted kidney, leading to chronic injury and fibrosis within the renal allograft over time. Unlike acute rejection episodes that are often more immediate and treatable with immunosuppressive therapy, CABMR is a more insidious process that can go unrecognized for a longer period. The ongoing presence of antibodies can result in chronic inflammation, vascular damage, and tissue fibrosis within the transplanted kidney, ultimately leading to irreversible damage and loss of graft function. Early detection of CABMR is challenging but essential for optimizing long-term outcomes in transplant recipients. Monitoring for signs of chronic rejection, such as unexplained decline in kidney function, proteinuria, and histological evidence of chronic injury on biopsy, is crucial in identifying patients at risk for graft loss due to CABMR. Management of CABMR typically involves a combination of immunosuppressive adjustments, targeted antibody therapies, and close monitoring of graft function. However, the outcomes of CABMR remain challenging, and prevention strategies are limited. Therefore, efforts to minimize the development of donor-specific antibodies through proper donor-recipient matching and adherence to immunosuppressive therapy are key in mitigating the risk of CABMR and improving long-term graft survival in renal transplant recipients.

Answer 111

The correct answer is Presence of donor-specific antibodies (DSA) The presence of donor-specific antibodies (DSA) in renal transplant recipients is a significant Alloantigen-dependent factor that plays a critical role in influencing long-term graft survival. DSAs are antibodies produced by the recipient’s immune system that specifically target antigens present on the donor organ. When DSAs recognize these donor-specific antigens, they can trigger an immune response that leads to antibody-mediated rejection (AMR). AMR is a form of rejection characterized by the binding of DSAs to antigens on the transplanted kidney, resulting in activation of the complement system, recruitment of inflammatory cells, and ultimately damage to the renal allograft. If left unchecked, AMR can progress to chronic antibody-mediated rejection (CAMR), a process that involves ongoing antibody-mediated damage to the graft, leading to fibrosis, vascular changes, and ultimately graft dysfunction. The impact of DSAs on long-term graft survival is significant because these antibodies can persist over time and continue to target the transplanted kidney, even years after the initial transplantation. The presence of DSAs is associated with an increased risk of AMR, graft dysfunction, and ultimately graft loss. Therefore, monitoring for the development of DSAs through regular antibody screening and histological evaluation is essential in identifying patients at risk for antibody-mediated rejection and implementing targeted interventions to prevent long-term graft damage. Management of DSAs often involves a combination of strategies aimed at reducing antibody levels, such as plasmapheresis, intravenous immunoglobulin therapy, and changes in immunosuppressive regimens. Additionally, desensitization protocols may be considered for highly sensitized patients to reduce the risk of antibody-mediated rejection and improve long-term graft outcomes. So, in summary, the presence of donor-specific antibodies is an important Alloantigen-dependent factor that significantly impacts long-term graft survival in renal transplant patients. Understanding the role of DSAs in triggering antibody-mediated rejection and implementing strategies to monitor and manage these antibodies is essential in optimizing transplant outcomes and preserving renal allograft function over time.

NEPHROLOGY Flashcards

(135 cards)